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Brain tumors are the second most common neoplasms in children and their 
incidence is also relatively high in the adult population, with gliomas accounting for 
the majority of cases. So far, the treatment protocols available for gliomas did not 
improve the prognosis, mainly due to a phenomenon known as multidrug resistance. 
Thus, research has now been aimed to identify the mechanisms leading to 
gliomagenesis and it was recently suggested that neural stem/progenitor cell or 
early-differentiated cell type lineages might be in the origin of glioma. Therefore, the 
main goals of the present work are: a) to identify which developmental stage, in the 
neural stem cell (NSC) differentiation process towards astrocytes, is most similar to 
the glioma phenotype and b) to find successful adjuvant molecules for temozolomide 
(TMZ), a chemotherapeutic agent. 
The GL261 mouse glioma cell line was cultured until 7 days in vitro and some 
tumor-related factors were determined in glioma cells and compared with astrocytes 
differentiated from mouse neural stem/precursor cells (neurospheres, NS). Moreover, 
we also evaluated the potential beneficial effect of TMZ treatment in the presence of 
the bile acid glycoursodeoxycholic acid (GUDCA) or the multidrug resistance-
associated protein 1 (Mrp1) inhibitor MK-571. Finally, we have assessed the effect of 
both GUDCA and MK-571 on the expression of CXCR4, a chemokine receptor.  
The analysis of tumor-related factors showed that during GL261 maturation, there 
is a decrease on the expression of the vascular endothelial growth factor (VEGF) as 
well as on the activity of the matrix metalloproteinases MMP-9 and MMP-2, which is 
associated with an increase on S100B release. Also, the Mrp1 presents a peak of 
expression at 5 DIV. Although not as evident as we were expecting, the NS 
proliferating stage seems to be the phenotype most similar to glioma cells, 
suggesting that the origin of glioma might be somehow associated with NSC 
malignant transformation. Moreover, TMZ therapy appears to be improved by the 
synergistic effect of GUDCA or Mrp1 inhibition, since it was observed a further 
reduction on cell viability and cell cycle arrest at the G2/M phase. Conversely, 
GUDCA or MK-571 seem to improve the migratory ability of GL261, by the induction 
of increase of CXCR4 levels. 
Efforts to enlarge knowledge about the pathways implicated on a malignant 
alteration during neural development as well as to further understand how to improve 
the current therapy, would allow a more specific targeting and consequently, an 
increased survival of glioma patients. 
 
Keywords: GL261 glioma cells; glycoursodeoxycholic acid; MK-571; neural stem 
cells proliferation and differentiation; temozolomide; tumor-related factors 
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Os tumores cerebrais são as segundas neoplasias mais comuns em crianças e a 
sua incidência é também relativamente elevada na população adulta, sendo os 
gliomas os mais frequentes. Até agora, os tratamentos disponíveis para gliomas não 
melhoraram o prognóstico, principalmente devido a um fenómeno conhecido como 
resistência a múltiplas drogas. Assim, atualmente a investigação tem como objetivo 
identificar os mecanismos que levam à gliomagénese e foi recentemente sugerido 
que células estaminais/progenitoras neurais ou no início da diferenciação podem 
estar na origem dos gliomas. Desta forma, os principais objetivos do presente 
trabalho são: a) identificar qual o estadio de desenvolvimento, no processo de 
diferenciação de células estaminais neurais para astrócitos, é mais parecido com o 
fenótipo de glioma e b) encontrar moléculas adjuvantes eficazes na terapia com 
temozolomida (TMZ), um agente quimioterapêutico. 
As células de glioma de ratinho GL261 foram mantidas em cultura durante 7 dias 
in vitro e alguns fatores relacionados tumores foram determinados em células de 
glioma e comparadas com os astrócitos diferenciados a partir de células 
estaminais/progenitoras de ratinho (neuroesferas, NS). Além disso, foram 
igualmente avaliados os potenciais efeitos benéficos do tratamento com TMZ na 
presença do ácido glicoursodesoxicólico (AGUDC) ou de um inibidor da proteína 
associada à  resistência a multidrogas (Mrp1), o MK-571. Finalmente, foi avaliado o 
efeito quer do GUDCA, quer do MK-571 na expressão de CXCR4, um recetor de 
quimocinas. 
A análise dos factores relacionados com tumores mostrou que, durante a 
maturação das células GL261, há uma diminuição na expressão do factor de 
crescimento endotelial vascular (VEGF), bem como na actividade das 
metaloproteinases MMP-9 e MMP-2, associado a um aumento da libertação de 
S100B. Além disso, a Mrp1 apresenta um pico de expressão ao 5 DIV. Apesar de 
não ser tão evidente como esperávamos, o estadio de NS parece ser o fenótipo 
mais semelhante com as células de glioma, o que sugere que a origem dos gliomas 
pode estar de alguma forma associada à transformação maligna das CEN. Além 
disso, a terapia com TMZ parece ser mais eficaz pelo efeito sinergético do GUDCA 
ou inibição da Mrp1, uma vez que se observou uma redução na viabilidade celular e 
paragem do ciclo celular na fase G2/M. Por outro lado, o GUDCA ou MK-571 
parecem melhorar a capacidade de migração das GL261, através da indução do 
aumento dos níveis de CXCR4. 
Um melhor conhecimento  sobre as vias implicadas em alterações malignas 
durante o desenvolvimento neural, bem como sobre novas formas de melhorar a 
actual terapia, permitirá o uso de esquemas terapêuticos mais direccionados e 
Resumo 
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específicos e, consequentemente, um aumento da sobrevivência dos pacientes que 
apresentam gliomas. 
 
Palavras chave: células de glioma GL261; ácido glicoursodesoxicólico; MK-571; 
proliferação e diferenciação de células estaminais neurais; temozolomida; factores 
relacionados com tumores 
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1. Brain tumors 
The term “brain tumor” refers to a group of neoplasms, with high incidence both 
in children as well as in the adult population, and on these, they mainly occur in the 
elderly (Sutter et al., 2007). Each neoplasm has its own biology, diagnosis and 
treatment. However, the clinical presentation, diagnosis and initial treatment are 
similar for most tumors. 
Nowadays, tumors of the central nervous system (CNS) are mostly classified by 
the World Health Organization (WHO) guidelines, which facilitate the communication 
throughout the world. A brain tumor can be primary, if the tumor starts in the brain 
and secondary (or metastatic), if it results from somewhere else in the body (ABTA, 
2010). 
 
 
1.1. Classification of gliomas 
Gliomas, the most common form of primary brain tumors are characterized by a 
great heterogeneity both histologically and clinically, as well as by diverse grades of 
malignancy. The most recent classification of gliomas was described by WHO in 
2007 based mainly on three parameters: cell type, malignancy grade and tumor 
location (Louis et al., 2007). 
 
a) Classification Based on Cell Type 
This type of classification is based on the histological characteristics of the cells, 
according to the phenotypic and morphologic similarities of the tumor cells with those 
of different types of glial cells, such as astrocytes, oligodendrocytes and ependymal 
cells. Thus, gliomas can be classified as astrocytomas, oligodendrogliomas, 
ependymomas and also oligoastrocytomas (or mixed gliomas). Among all these 
types of tumors, astrocytomas are the most common. 
 
b) Classification Based on Malignancy Grade 
Grading of tumors facilitate the treatment and the prediction of their outcome. The 
grade indicates its degree of malignancy and it is assigned based on the tumor’s 
microscopic examination using criteria: like similarity to normal cells (atypia), rate of 
growth (mitotic index), indication of uncontrolled growth, dead tumor cells in the 
center of the tumor (necrosis), potential for invasion and/or spread (infiltration) based 
on whether or not it has a definitive margin (diffuse or focal), and blood supply 
(vascularization) (Fig.I.1). When gliomas contain several grades of cells, the grade is 
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determined by the highest or most malignant grade of cells, even if most of the tumor 
is a lower grade kind. 
 
 
Fig. I.2. – Histophatologic progression of infiltrating astrocytoma to glioblastoma 
multiforme (GBM) according to the WHO classification. The normal brain white matter 
(A), presents blood vessels (arrows) and cell density similar with an infiltrating astrocytoma 
grade II (B). Arrowhead shows that tumor cells of this grade II tumor can be found near the 
CNS parenchyma. Anaplastic astrocytoma (AA; grade III; C) is characterized by a higher 
number of cell and blood vessels density, which are often dilated or with thickness walls 
(arrows). AA cells also present an atypical morphology and some mitotic cells can be found. 
GBM (D) shows necrotic zones with pseudopalisading tumor cells (asterisk within necrotic 
center), which are usually surrounded by microvascular hyperplasia and vascular glomerules 
proliferation (arrow). From Brat et al. (2003). 
 
Grade I gliomas are benign and are typically related with long-term survival. The 
tumors exhibit a slow grow and a limited cell proliferation potential and have an 
almost normal appearance when viewed through a microscope. Surgery alone might 
be an effective treatment for these tumors. Grade II tumors have a relatively slow 
growing rate, a low-level of proliferative activity and a slightly abnormal microscopic 
appearance. They are in general infiltrative and some can recur as a higher-grade 
glioma. Grade III tumors are, by definition, malignant. The cells of a grade III tumor 
are actively reproducing abnormal cells, which grow into nearby normal brain tissue. 
These tumors tend to recur, often as a higher grade. In most cases, it is necessary to 
receive adjuvant radiation and/or chemotherapy. The tumors of grade IV are the 
most malignant. In addition to the strange appearance, they have a high mitotic 
activity and can easily spread into the surrounding normal brain tissue. These tumors 
have also an enormous ability to form new blood vessels so they can maintain their 
rapid growth. Necrosis zones are usually associated with a rapid evolution and fatal 
outcome. The glioblastoma multiforme (GBM), sometimes referred only as 
A B C D 
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glioblastoma, is the most common between grade IV tumor (Louis et al., 2007; 
Ohgaki, 2009). 
 
c) Classification Based on Tumor Location 
Gliomas can also be classified regarding their location, whether above or below 
the tentorium, a membrane that separates the cerebrum (above) from the cerebellum 
(bellow). Hence, they are defined as supratentorial, which develop above the 
tentorium, and as infratentorial, which develop below the tentorium. The 
supratentorial and the infratentorial gliomas correspond to 70% of the tumors in 
adults and children (Louis et al., 2007).  
 
 
1.2. Epidemiology of gliomas 
The peak of gliomas onset is around 50-55 years, which makes them a strongly 
age-related pathology. The incidence of brain tumors tends to be highest in 
developed and industrialized countries. In Western Europe, North America and 
Australia there are about to 6-11 new cases of primary intracranial tumors per 100 
man individuals and to 4-11 new cases in the women population (Ohgaki and 
Kleihues, 2005; Ohgaki, 2009). Ethnic differences in the vulnerability to develop of 
brain tumors cannot be excluded. Caucasians are more susceptible than African or 
Asian people. Some reports indicate that the incidence rate of gliomas is 
approximately twice in whites when compared to blacks. In addition, in Japan, 
gliomas are about half as frequent as in the United Sates of America (Ohgaki and 
Kleihues, 2005; Ohgaki, 2009). 
With the exception of pilocytic astrocytoma (WHO grade I), survival of glioma 
patients is still poor and one of the factors for this is the older age at diagnosis. 
Mortality rates from CNS tumors are similar to the incidence rate, i.e., around to 4-7 
cases per 100,000 persons per year in men and to 3-5 cases in women, throughout 
the geographical areas referred above (Ohgaki and Kleihues, 2005; Ohgaki, 2009). 
 
 
1.3. Signaling pathways regulating gliomagenesis  
It is recognized that morphological changes during the malignant transformation, 
reflect the sequential acquisition of genetic alterations. Although primary and 
secondary tumors differ on the genetic level in many ways, there are some common 
genetic abnormalities, which are considered as hallmarks of gliomas. So far, a 
variety of studies have identified DNA copy number alterations and mutations as 
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recurrent events on gliomagenesis, suggesting the involvement of tumor suppressor 
genes and oncogenes (Fig. I.2) in tumor initiation and progression (Furnari et al., 
2007; Ohgaki, 2009). 
The first studies identified the existence of mutations in the epidermal growth 
factor receptor (EGFR) gene, encoding the receptor for the epidermal growth factor 
(EGF) (Van Meir et al., 2010). Mutation in EGFR glioma enhances tumorigenic 
behavior by reducing apoptosis and increasing proliferation (Furnari et al., 2007). 
Later, further analysis identified the p53 tumor suppressor gene, as important for, 
which is involved in the regulation of cell cycle progression and apoptosis in 
response to a wide variety of stress signals, including DNA damage. Upon exposure 
to genotoxic agents, p53 is stabilized, accumulates in the nucleus, binds and 
transcriptionally regulates the promoters of potential effector genes. Since p53 
function is critical for normal cell growth and development, its activity is tightly 
regulated by phosphorylation, which is the first step to induce stabilization of p53 
(Carmo et al., 2011). This pathway is nearly invariably altered in sporadic gliomas 
and frequent in the beginning of secondary glioblastomas (Furnari et al., 2007; 
Carmo et al., 2011). The next genes discovered were the p16 cell cycle inhibitor, and 
the phosphatase and tensin homolog (PTEN), acting both as tumor suppressors. The 
p16 is responsible for the slow down of the cell cycle progression, whereas PTEN is 
a negative regulator of the phosphoinositide 3–kinase (PI3K) pathway, a major 
signaling pathway that stimulates cellular proliferation in response to growth factor 
stimulation (Westphal and Lamszus, 2011). Inactivation of PTEN is associated with 
increased angiogenesis, a parallel process in the progression of high grade gliomas 
(Furnari et al., 2007). In fact, PTEN mediates a variety of biological functions like 
apoptosis, inflammation and immunity (Westphal and Lamszus, 2011).  
Recently, some mutations were identified at the level of the genes encoding 
isocitrate dehydrogenase 1 (IDH1) (and to a lesser extent IDH2) and retinoblastoma 
(RB) in lower grade gliomas and in a subset of glioblastomas. IDH1 mutation is 
associated with longer survival of patients with secondary glioblastoma and one 
consequence of its raised expression is an altered pattern of DNA methylation in 
gene promoter regions, leading to epigenetic silencing (Westphal and Lamszus, 
2011). RB blocks proliferation by binding and sequestering the E2F family of 
transcription factors, which prevents the activation of essential genes for progression 
through the cell cycle (Furnari et al., 2007). Moreover, mutations in the ERBB2 gene 
have also been found as recurrent event in primary glioblastomas (Westphal and 
Lamszus, 2011). 
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Fig. I.2. - Pathways that mediate the development of glioblastoma. Distinct molecular 
alterations correlate with the clinical development of gliomas. EGFR, endothelial growth factor 
receptor; IDH1, Isocitrate dehydrogenase 1; LOH, Loss of heterozygosity 10q; P16 
INK4a
, 
Cyclin-dependent kinase inhibitor 2A; PTEN, Phosphatase and tensin homolog; TP53, tumor 
protein 53. Adapted from Sulman (2009). 
 
Although histologically indistinguishable, GBM can occur in different age groups 
and present distinct genetics alterations affecting similar pathways. The 
understanding and identification of these alterations will assist a more correct 
diagnosis. 
 
 
1.4. Tumorigenic properties 
The tumorigenic properties that are the most responsible for the initiation and 
maintenance of tumor include tumor cell invasion, angiogenesis, resistance to 
therapy and autophagy, which will be further discussed. 
 
 
 
Glioma cell of origin 
Low-grade astrocytoma 
 
TP53 mutation (~ 60%) 
Anaplastic astrocytoma 
 
TP53 mutation (~ 50%) 
Secondary glioblastoma 
 
LOH 10q (~ 60%) 
EGFR amplification (~ 5%) 
P16
INK4a
 deletion (~ 20%) 
TP53 mutation (~ 70%) 
PTEN mutation (~ 5%) 
IDH1 (? %) 
Primary glioblastoma 
 
LOH 10q (~ 70%) 
EGFR amplification (~ 30%) 
P16
INK4a
 deletion (~ 30%) 
TP53 mutation (~ 30%) 
PTEN mutation (~ 30%) 
IDH1 (? %) 
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1.4.1. Tumor cell invasion 
The infiltrative nature of tumors makes curative surgical resection nearly 
impossible and contributes to the poor prognosis and short median survival of 
patients (Choe et al., 2002). 
Invasion of tumor cells into adjacent brain structures occurs through the 
activation of matrix metalloproteinases (MMPs). MMPs are a family of zinc-
dependent endopeptidases that mediate the degradation of protein components of 
the extracellular matrix (ECM) and of basement membranes (Choe et al., 2002; 
Hagemann et al., 2012). Degradation of the ECM by MMPs not only enhances tumor 
invasion, but also affects tumor cell behavior and leads to cancer progression. MMPs 
can be classified as collagenases (MMP1, MMP8 and MMP13), stromelysins (MMP3, 
MMP10, MMP11, MMP7 and MMP26), gelatinases (MMP2 and MMP9) and as 
membrane-type (MMP14, MMP15, MMP16, MMP17, MMP24 and MMP25) (Rao, 
2003). 
MMPs enhance tumor-cell invasion and migration by degrading ECM proteins, 
activating signal transduction cascades that promote motility and solubilizing 
extracellular matrix-bound growth factors, in particular by cleaving laminin-5 (Choe et 
al., 2002; Rao, 2003; Hagemann et al., 2012). In fact, it was observed that 
interference with MMP-9 and one of its upstream regulators by RNA interference 
lead to a reduction in tumor growth and invasion in a mouse model. MMP-9, MMP-2 
and its activator MMP-14 are involved in migration and invasion of human GBM cells 
and the first clinical trials using the MMP inhibitor, marimastat, in combination with 
chemotherapy have recently been performed in GBM patients (Hagemann et al., 
2012). 
In addition, MMPs also play a central role in a number of physiological processes, 
such as cell growth and development (by cleaving and activating some growth 
factors, as the transforming growth factor-β), differentiation, angiogenesis (by 
increasing the bioavailability of pro-angiogenic growth factors) and apoptosis (Lu et 
al., 2010; Ponnala et al., 2011). Very recently, it was published a review that 
summarizes the currently available data on the expression of MMPs in human 
glioblastomas (Hagemann et al., 2012). 
 
Besides MMPs, S100B is also related with tumor cell invasion. This protein is a 
member of a multigenic family of Ca2+-binding protein of the EF-hand type, and is 
located diffusely in the cytoplasm and associated with membranes and certain 
cytoskeleton elements (Brozzi et al., 2009; Zhang et al., 2011). S100B has been 
implicated in the regulation of both intracellular and extracellular activities, such as 
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regulation of the state of microtubules assembly and type III intermediate filaments, 
some enzyme activities, and cell proliferation. High levels of S100B are found in 
certain cancer cells, reason why it has been proposed that it contributes to 
tumorigenesis by inhibiting the function of p53 protein and by regulating cell 
proliferation and differentiation by stimulation of kinases activation (Brozzi et al., 
2009; Zhang et al., 2011). Being a chemotactic molecule, S100B protein stimulates 
microglia migration via RAGE-dependent up-regulation of chemokine expression and 
release (Bianchi et al., 2011). Thus, we can hypothesize that this molecule may 
perform a pivotal function in tumor cell invasion and metastasis. 
  
 Other molecules also associated to tumor cells invasion are chemokines, which 
are a family of chemotatic cytokines involved in multiple biological functions, as 
leukocyte migration, hematopoiesis, mitosis, apoptosis, survival, angiogenesis and 
tumor cell growth (Carmo et al., 2010; Calatozzolo et al., 2011). The most important 
chemokine associated with tumorigenesis process and metastasis is the stroma-cell-
derived factor 1 (SDF-1/CXCL12) and its receptor, the CXCR4, a G-protein, which 
expression is upregulated by hypoxia, via hypoxia-inducible factor 1 (HIF-1α) and 
vascular endothelial growth factor (VEGF) (Calatozzolo et al., 2011). The activation 
of CXCR4 by CXCL12 regulates numerous essential processes such as cardiac and 
neuronal development, stem cell motility, and as a pro-angiogenic factor (Calatozzolo 
et al., 2011). Regarding brain tumors, it has been shown that both CXCR4 and 
CXCL12 were overexpressed when compared with normal tissue, predominantly in 
necrosis areas and angiogenesis (Calatozzolo et al., 2011), what is correlated with 
the infiltrative extension of the tumor (Carmo et al., 2010). In vivo and in vitro studies 
demonstrated that CXCL12 promotes tumor growth and inhibits apoptosis through 
Erk1/2 and Akt pathways and also mediated glioma chemotaxis (Calatozzolo et al., 
2011). On the other hand, CXCR4 expression in malignant gliomas has been 
associated with poor prognosis in patients and mouse models (Calatozzolo et al., 
2011). Thus, the importance that this CXCL12/CXCR4 axis has in tumorigenesis 
makes it a great therapeutic target in glioma treatment.  
 
 
1.4.2. Angiogenesis 
Studies support that angiogenesis, the formation of new vessels from pre-existing 
ones, is required for tumor growth. Thus, during the last three decades, intensive 
research has been performed to characterize the angiogenesis process and many 
angiogenesis-related factors or genes have been identified (Jouanneau, 2008). 
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Angiogenesis is characterized by a series of steps including degradation of the 
basement membrane, endothelial cell proliferation, invasion of the surrounding 
stroma and structural reorganization into a novel functional vascular network through 
the recruitment of perivascular supporting cells (Jansen et al., 2004). The complexity 
of the process implies the involvement of multiple regulatory factors, such as growth 
factors, adhesion molecules and matrix-degrading enzymes. Malignant gliomas 
exhibit many vessel-related pathological features (Yamanaka and Saya, 2009). 
These features include marked endothelial proliferation, and tortuous disorganized 
vessels of higher permeability, larger diameters and thicker basement membranes 
than vessels found in normal tissues. Aberrant microvasculature typically appears as 
glomeruloid tufts, proliferations of microvessels consisting of multilayered mitotically 
active endothelial and perivascular cells (Jain et al., 2007). 
The most important growth factor in angiogenesis is VEGF, which has highly 
specific mitogenic and chemotactic activity on endothelial cells (Kargiotis et al., 
2006). Up-regulation of VEGF seems to be triggered by hypoxia through HIF-1 and 
mediated by two mechanisms (Jansen et al., 2004; Kargiotis et al., 2006). Through 
multiple regulatory mechanisms, HIF acts as a delicate sensor leading to a rapidly 
cell response to changes in environmental levels of oxygenation (Kaur et al., 2005). 
First, hypoxia induces the activation of VEGF gene transcription through an HIF-
dependent mechanism, mediated by HIF-1 binding to the VEGF promoter, resulting 
in increased gene transcription. The second mechanism upregulates VEGF mRNA 
levels by regulating mRNA stability. Regulation is finely tuned to the availability of 
oxygen because HIF-1a, the oxygen-sensitive subunit of the HIF-1 complex, is stable 
in hypoxia (Jansen et al., 2004). VEGF is predominantly located in the 
pseudopalisading cells surrounding hypoxic/necrotic foci, which is likely due to 
hypoxic induction. In fact, besides abundant microvessels, regional necrosis is 
another common pathological feature in glioma tissues and emerging evidence has 
suggested that hypoxia is an important modulator in the process of glioma 
angiogenesis (Jensen, 2009). Thus, due to obvious and aggressive vascular 
proliferation and very poor prognosis, many antiangiogenic drugs were rushed for 
approval in clinical trials for glioma patients. Unfortunately, under experimental and 
clinical conditions, antiangiogenic therapy has led to increased invasion and higher 
recurrence rates (Thurston and Kitajewski, 2008). 
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1.4.3. Resistance to chemoradiotherapies 
Although chemo and radiotherapy remain the adjuvant treatments of brain 
cancer, these treatments fail to cure the majority of patients mainly due to 
chemoresistance. Several mechanisms may contribute to the development of 
therapeutic resistance, including cell intrinsic factors, selection of resistant genetic 
subclones, and microenvironmental factors. 
ATP-binding cassette (ABC)-transporters are transmembrane proteins that utilize 
ATP hydrolysis to transport substrates from the intracellular to the extracellular 
compartment (Atkinson et al., 2009), acting as drug efflux pumps and decreasing the 
intracellular levels of various cytotoxic agents (Benyahia et al., 2004; Lebedeva et al., 
2011). The multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of 
a subfamily of the ABC-transporters superfamily. It was discovered by Cole et al. 
(Cole et al., 1992), that described it as responsible for multidrug resistance of tumors 
(Begley, 2004). In addition to its ability to confer resistance in tumor cells, multi-
resistance protein 1 (MRP1) is ubiquitously expressed in normal tissues and is a 
primary active transporter of glutathione (GSH), although it also transports 
unmodified xenobiotics that often require GSH (Fig. I.3) (Leslie et al., 2001). In 
untreated gliomas, an overexpression of MRP1 has been reported in about 70% of 
cases, with a higher expression in high-grade gliomas, particularly glioblastoma 
(Benyahia et al., 2004; Lebedeva et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. I.3. - Multidrug resistance mechanism of the multidrug resistance-associated 
protein 1 (Mrp1). Mrp1, a transmembrane protein, functions as an ATP-dependent efflux 
pump by carrying cytotoxic drugs out from brain cells mediated by the conjugation with 
glutathione (GSH), particularly in glioma cells. Adapted from Bredel et al. (2001). 
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Besides MRP1 phenotype, resistance to chemotherapy is often caused by 
elevated levels of enzymes involved in intracellular drug mechanism, including 
MGMT, as already described, contributing to resistance to alkylating agents. 
 
 
1.4.4. Autophagy 
Autophagy, also known as the programmed cell death type II, is a conserved 
process that degrades and recycles organelles and portions within cytosol. The 
intracellular molecules and organelles, such as endoplasmic reticulum, mitochondria, 
and peroxisomes, are sequestered into double-membrane structures called 
autophagosomes (autophagic vesicles) (Fan et al., 2010). The C-terminal fragment 
of microtubule-associated protein light chain 3 (LC3, which is essential for 
autophagy) is cleaved to a cytosolic form LC3-I, which is further converted to LC3-II, 
a 16-kDa protein that localizes into autophagosomal membranes.  Autophagosomes 
then fuse with lysosomes, forming autophagolysosomes, which promote the 
degradation of intracellular contents by lysosomal enzymes (Fan et al., 2010; Lin et 
al., 2012). Autophagy thus enables the cell to eliminate and recycle proteins or 
organelles to sustain metabolism and can be recognized in part by formation of LC3-
II punctae (Fan et al., 2010), since the amount of LC3-II correlates with the number 
of autophagosomes. Therefore, LC3-II is considered an autophagy marker (Lin et al., 
2012).  
This type of cell death is also highly adaptable and can be modified to digest 
specific cargoes to bring about selective effects in response to numerous forms of 
intracellular and extracellular stress. It is not a surprise, therefore, that autophagy 
has a fundamental role in cancer and that perturbations in autophagy can contribute 
to malignant disease. However, there are conflicting reports suggesting that 
autophagy can be both oncogenic and tumor suppressive, perhaps indicating that 
autophagy has different roles at different stages of tumor development. Recent data 
point out that this process may play a critical role in the benign to malignant transition 
that is also central to the initiation of metastasis (Macintosh et al., 2012). 
 
 
1.5. Diagnosis and treatment 
The classification of a tumor stage determines if it has spread beyond the site of 
its origin and this information often influences treatment recommendations and 
prognosis. The first steps of the diagnosis consist in making the medical history and 
a basic neurological exam, which analyzes diverse parameters, including memory. 
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Thereafter, if the result is suspicious, additional testing as scans, like Magnetic 
Resonance Imaging (MRI) and Computerized Tomography (CT) or Positron 
Emission Tomography (PET), x-rays or laboratory tests are performed. During and 
after treatment, it is recommended to repeat these tests in order to follow the 
evolution or stage of the disease (Omay and Vogelbaum, 2009). 
Until recently, treatment decisions regarding malignant gliomas began only when 
diagnosis was established by standard histopathology only, what has been for the 
most cases inexact because of the diversity that exists within these tumors, even 
among those of the same grade and histologic type (Sulman et al., 2009). However, 
over the past 10 years, there has been an increasing use of molecular markers, such 
as methylation of the methylguanine methyltransferase (MGMT) promoter and 
mutations of IDH-1 (Sulman et al., 2009), in the assessment and management of 
adult malignant gliomas. Some molecular signatures are used diagnostically to help 
pathologists in the classification of tumors, whereas others are used to estimate 
prognosis for patients. Most important, those markers are used to predict response to 
certain therapies, thereby directing clinicians to a particular treatment while avoiding 
other potentially deleterious. It has also paved the way for the possibility of 
personalized medicine, in which a patient’s tumor expression profile can be used to 
design a treatment specific to that individual’s tumor with the greatest possibility of 
response (Sulman et al., 2009). Thus, large-scale genome-wide surveys have been 
used to identify new biomarkers that have been rapidly developed as diagnostic and 
prognostic tools (Jansen et al., 2010). 
Prognosis and therapeutic approaches depend on the type of tumor, as well as 
on the location and its degree of malignancy. However, in most cases, therapy starts 
with surgical removal of the tumor follow by radio and chemotherapy. Since the mid-
80s, various compounds for the treatment of gliomas have been studied, such as 
cisplatin and carmustine, but none of them have proved to be effective in increasing 
survival and/or improving patients outcomes (Parney and Chang, 2003). At the 
present, the chemotherapeutic drugs most used are nitrosourea, etoposide, cisplatin, 
vincristine and temozolomide (TMZ), being the first-line treatment with radiotherapy 
and concomitant chemotherapy with TMZ. These compounds were shown to be 
relatively effective used either as monotherapy or in combination with other agents 
like procarbazine, lomustine, resveratrol, irinotecan and bevacizumab, among others 
(Argyriou et al., 2009). In fact, Lin and colleagues described a synergistic effect of 
TMZ and resveratrol, which reduced tumor volumes by inhibiting autophagy of glioma 
cells after TMZ treatment, inducing apoptosis (Lin et al., 2012). This suggests that 
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combined therapy could improve the efficacy of chemotherapy for brain tumors (Lin 
et al., 2012). 
 
 
1.5.1.  Temozolomide as a chemotherapeutic agent 
TMZ was developed in the 80s by the UK Cancer Research as one of a series of 
novel imidazotetrazinones, and it was initially developed with the intent to treat 
patients with malignant melanoma metastases in the brain. However, it also showed 
activity in relapsed GBM patients, encouraging further investigation. The first in vivo 
studies (phase I trial), in early 1990, confirmed the antitumoral potential of TMZ, 
which also exhibited less side-effects than the conventional chemotherapeutics drugs 
(Mason and Cairncross, 2005). In 1999, TMZ was approved by the FDA and, 
subsequently, the European Organization for Research and Treatment of Cancer 
(EORTC) and the National Cancer Institute of Canada (NCIC) demonstrated an 
improved median survival, of the treatments with TMZ representing the first trials in 
which such improvement was seen, since those performed with radiation therapy 
(RT) in the mid-1970s (Villano et al., 2009). In 2002 and 2005 the results of phase II 
and phase III trials were, respectively, published (Stupp et al., 2002, 2005), showing 
the safety and efficacy of RT alone versus TMZ plus RT followed by TMZ 
monotherapy (Stupp regimen or EORTC-NCIC) in patients with newly diagnosed 
GBM. In the randomized phase III study, at a median follow-up of 28 months, the 
median survival was 14.6 months with RT plus TMZ compared with 12.1 months for 
RT alone. The 2- and 5-year survival were also improved (26,5% against 10,4%) 
(Stupp et al., 2005; Villano et al., 2009). Nevertheless, the prognosis of patients are 
still poor, once fewer than 3% of patients are still alive at 5 years after diagnosis 
(Ohgaki, 2009). 
 
 
Fig. I.4. - Chemical structure of temozolomide (TMZ) and of its metabolites. After 
absorption, TMZ is spontaneously hydrolyzed at physiologic pH into the active metabolite 
MTIC (5-(3-methyltriazen-1-yl)imidazol-4-carboxamid), which is quickly converted to 5-
aminoimidazole-4-carboxamide (AIC) and to the electrophilic alkylating methyldiazonium 
cation that transfers a methyl group to DNA. From Villano et al. (2009). 
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TMZ is a DNA alkylant agent, characterized by rapid and nearly complete oral 
absorption (Friedman et al., 2000; Villano et al., 2009). After absorption, the 
compound is spontaneously hydrolyzed at physiologic pH into the active metabolite 
MTIC (5-(3-methyltriazen-1-yl)imidazol-4-carboxamid) (Fig. I.4). Both TMZ and MTIC 
are able to cross the blood brain barrier. The active form of TMZ shows a plasma 
peak concentration within 30 to 90 min following uptake, and a half-life of 2 hours. 
MTIC is then quickly converted to 5-aminoimidazole-4-carboxamide (AIC) and to the 
electrophilic alkylating methyldiazonium cation that transfers a methyl group to DNA. 
Methylation of O6 position of guanine (O6-meG) explains the cytotoxicity of TMZ, 
which leads to inhibition of proliferation or cell death, late apoptosis, senescence 
(Gunther et al., 2003), autophagy, and cell cycle arrest (Fig. I.5) (Hirose et al., 2001; 
Carmo et al., 2011).  
 
Fig. I.5. – Mechanisms of activity of temozolomide (TMZ) as an enhancer therapeutics. 
O6-meG (O6 position of guanine) DNA adducts, as the DNA DSB (DNA double-straind 
breaks), are responsible for the cytotoxic effect of TMZ. MGMT (O6-methylguanine-DNA 
methyltransferase) repairs the lesions, resulting in resistance to TMZ. When MGMT is 
depleted or suppressed by methylation of the gene promoter, cytotoxicity of TMZ is 
enhanced.  
 
 
The O6-G-alkylation is reversed by the O6-methylguanine-DNA 
methyltransferase (MGMT) and thus high levels of MGMT are thought to contribute 
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to the resistance to TMZ. MGMT repairs the O6-meG lesion by transferring the 
methyl group to its own cysteine residue. Methylated MGMT is then degraded. Thus, 
MGMT is considered a ‘suicide’ repair protein, and new MGMT must be synthesized 
in order to continue DNA repairing. Conversely, methylation of the promoter of the 
MGMT gene silences the gene, and would be expected to enhance the cytotoxicity of 
O6-meG lesions (Villano et al., 2009). 
 
 
1.5.2. Ursodeoxycholic acid (UDCA) and its glyco- (GUDCA) and tauro- 
(TUDCA) conjugated species 
Ursodeoxycholic acid (UDCA), the 7β-hydroxy epimer of chenodeoxycholic acid, 
is an endogenous bile acid that has been widely used for the treatment of 
hepatobiliary disorders since the mid-1980s (Lazaridis et al., 2001) and is also 
suggested to have a potential role in the treatment of non-liver diseases associated 
with increased levels of apoptosis, since as been considered an anti-apoptotic agent 
(Rodrigues and Steer, 2001). Following oral administration, UDCA is conjugated with 
taurine and glycine in the liver, originating tauroursodeoxycholic acid (TUDCA) and, 
mostly, glycoursodeoxycholic acid (GUDCA, 79,8%), respectively (Lazaridis et al., 
2001; Rudolph et al., 2002). Thus, GUDCA is the conjugate form of UDCA with 
highest clinical relevance. 
It was demonstrated that UDCA, as well as its conjugates act as cytoprotective 
agents, stabilizing cell and mitochondrial membranes and preventing cytochrome c 
release, consequently reducing cellular apoptosis (Guldutuna et al., 1993; Rodrigues 
et al., 2000; Silva et al., 2001). Additionally, UDCA is able to suppress the production 
of pro-inflammatory cytokines by inactivation of the NF-κB pathway in different cell 
types (Sola et al., 2003; Joo et al., 2004; Schoemaker et al., 2004; Shah et al., 
2006). Our most recent findings showed that GUDCA suppresses the production of 
the proinflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-1β 
in astrocytes (Brito et al., 2008). Moreover, it was recently suggested that the 
cytoprotective mechanism of both UDCA and its conjugates, is mediated by a 
defense against oxidative stress, pointing to antioxidant properties of the molecule 
(Rodrigues et al., 2000; Lapenna et al., 2002; Serviddio et al., 2004; Perez et al., 
2006). 
There are no studies regarding the effect of GUDCA on glioma cells, but it has 
been described that UDCA was shown to prevent colon tumorigenesis and in 
addition to its antiproliferative effect, it induces tumor growth suppression, reinforcing 
its chemopreventive actions (Wali et al., 2002). 
Chapter I - Introduction 
 17 
2. Neural stem cells (NSCs) 
Stem cells have been described as cells with extensive proliferative potential, 
differentiation ability and self-renewal capability. NSCs can generate both neurons 
and glial cells (astrocytes, oligodendrocytes and microglia). Contrary to what was 
thought initially, NSCs exist also in the adult brain, playing an important role in 
neuronal plasticity (Temple, 2001). 
 
 
2.1. NSC in the developing and adult brain 
The CNS is formed over a short time in vertebrate embryogenesis and begins as 
a layer of neuroepithelial progenitors (NEPs) that rapidly form the neural tube (Merkle 
and Alvarez-Buylla, 2006). The development of the CNS includes several steps, such 
as the generation and differentiation of distinct cell lineages of neurons and glia, 
known to be descendents of multipotent NSCs. NEPs are cells specially located in 
the ventricular zone (VZ) of the neural tube, which has a great mitotic activity. Later, 
these cells move to the pial (external layer) of the neural tube as they progress 
through the mitotic cycle. In early embryonic phases, NEPs undergo mainly 
symmetric divisions, maintaining the stemness and increasing the stem cell pool, but 
then they divide asymmetrically to generate new stem cells that remain in the VZ, 
and intermediate progenitors (mostly neuronal precursors, but also glial) that migrate 
radially outward to its final position in the brain (Temple, 2001; Nicolis, 2007). At this 
point, the proliferating precursors cells originated may differentiate into more 
committed phenotypes, such as differentiated neurons or glial cells (astrocytes, 
oligodendrocytes or microglia). The differentiation of the neuroepithelial stem cells 
into neurons and glia proceeds in a temporal specific manner that is particular for 
each region of the developing neural tube. Before differentiate and in contrast with 
primary progenitors, intermediate progenitors may suffer one or more symmetrical 
divisions in the subventricular zone (SVZ), above the VZ, and the subgranular zone 
(SGZ) within the dentate gyrus of the hippocampus. Until birth, the SVZ increases in 
size and later decreases, persisting in adult life as SVZ (Merkle and Alvarez-Buylla, 
2006). 
In parallel to the onset of neurogenesis, radial glia (RG) cells appear to replace 
NEPs. RG cells function as stem cells for neurons (at early stages) and later for glia 
(Nicolis, 2007). Like NEPs, RG cells are a transiently population in the developing 
brain that divide in the VZ, still its differentiation potential is less broad than that of 
NEPs (Merkle and Alvarez-Buylla, 2006).  
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 Within the adult mammalian brain, two major germinal regions are the SVZ 
along the walls of the lateral ventricles, and the SGZ in the hippocampus. The SVZ 
contains the principal concentration of dividing cells in the adult brain. This region is 
formed by type B cells (or astrocyte-like neural stem cells), which are characterized 
by slow division. Type B cells generate actively proliferating type C cells (transient 
amplifying progenitors), which in turn produce immature neuroblasts (type A cells) 
that migrate to the olfactory bulb, where they can differentiate into interneurons. Type 
B cells express the astrocyte marker glial fibrillary acidic protein (GFAP), and it was 
recently shown that the potential of type B cells is limited (Ihrie and Alvarez-Buylla, 
2008). 
 The adult progenitors of the dentate gyrus are found in the SGZ of the 
hippocampus, where two types of cells can be identified according to their 
morphologies and expressions of molecular markers. Type 1 progenitors rarely 
divide, express GFAP and SRY (sex determining region Y)-box2 (Sox2), and have a 
radial process across the granular zone and ramify in the inner molecular layer. On 
the other hand, type 2 progenitors divide more frequently, display short processes 
and do not express GFAP. Some in vivo evidences demonstrated that type 1 
progenitor cells can give rise to neuroblasts that mature to neurons and, at least 
some of them, have self-renew ability and generate both astrocytes and neurons 
(Miller and Gauthier-Fisher, 2009). 
 
 
2.2. Applying NSC biology to glioma research: the brain tumor stem cells 
(BTSCs) hypothesis 
Brain tumor stem cells (BTSCs) term to often describes a subpopulation of stem 
cells, with properties such as self-renewal, unlimited proliferative potential, slow rates 
of division, resistance to toxic xenobiotics, high DNA repair capacity and ability to 
generate partially differentiated progenies (Foreman et al., 2009) (Fig.I.6). 
Divergent perspectives on the origin of a brain tumor fuel a debate that revolves 
around the theory BTSCs. This theory suggests that within a tumor, there is a small 
distinct cell population showing stem cell characteristics that are at the origin of the 
tumor, being responsible for tumor growth and maintenance. Corroborating this 
hypothesis, several groups studying brain tumors cells identified a minor population 
of cells in culture that are able to self-renew, form clonogenic neurospheres and 
differentiate into a broad range of cell types (Ignatova et al., 2002; Hemmati et al., 
2003; Singh et al., 2003; Galli et al., 2004; Huhn et al., 2005). These brain tumor 
cells expressing the cell surface marker CD133/Prominin1 (1-35% of the cell 
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population), also evidenced the stem cell marker Nestin, as well as molecular 
markers associated with neural precursors such as Sox2, Bmi1, Notch, Emx2, Pax6 
and Jagged1. Upon exposure to serum, these clonogenic neurospheres were able to 
differentiate into a mixed population of neurons (Tuj1+), astrocytes (GFAP+) and 
oligodendrocytes (PDGFR+), suggesting that they derived from a cell with 
multilineage differentiation capacity – a neural stem cell (Dirks, 2008). 
Later, other groups extended these findings to medulloblastoma, by evidencing 
that they express NSCs proteins, including Sox2, Bmi1 and Musashi1 (Hemmati et 
al., 2003). These findings confirm that (1) brain tumors contain undifferentiated 
neural precursors, (2) stem-like cells possess some of the molecular features of 
NSCs and (3) CD133+ cells can be used for the enrichment of tumor stem-like cells 
(Singh et al., 2003; Singh et al., 2004). 
 
 
Fig. I.6. – Characteristics of brain tumor stem cells (BTSCs). BTSCs are characterized by 
(1) extensive self-renewal and proliferation ability, (2) expression neural stem cell (NSC) 
markers, (3) capacity to generate differentiate multilineage, (4) karyotypic or genetic 
alterations as well as tumorigenicity in vivo or in vitro (5). 
 
 
Subsequently, studies in vitro through the injection of sorted CD133+ cells 
demonstrated that they could produce orthotopic tumors in the brain of NOD/SCID 
mice (an immunodeficient rodent), with common in vivo features of human GBM, 
such as extensive migratory and infiltrative capacity (Galli et al., 2004), whereas 
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injection of CD133- cells failed to form tumors (Singh et al., 2004). However, recent 
studies suggest a less clear distinction between the ability of CD133- and CD133+ 
cells to form orthotopic tumors (Bao et al., 2006; Beier et al., 2007). Although CD133 
expression seems to be related to stemness, it might only indicate an intermediate, 
adaptive state of a cell rather than a phenotype. It has been reported that CD133- 
isolated from primary GBM were equally capable of forming orthotopic tumors as the 
CD133+ population (Beier et al., 2007). These findings suggest that CD133 is not a 
reliable marker for the tumorigenic capacity of stem like cells. 
Currently, all stem-like glioma cells used in research are almost exclusively 
derived from glioblastoma and no defined cell type for its origin has emerged, most 
probably owing to the heterogeneity of the disease. Thus, the tumor brain stem cells 
fraction will require further purification. 
 
 
2.2.1. The origin of BTSCs 
Although there is an accumulating evidence that tumors contain a subpopulation 
with a tumor-initiating potencial, as described in the previous Section, the cell of 
origin of BTSCs has not been determined yet. At the present, it is unclear whether a 
tumor arises from NCSs, progenitor cells or differentiated cells that dedifferentiate 
into a stem-like state (Fig. I.7). 
Traditional neuro-oncology postulated that the differentiated glial cells were the 
cells at the origin of gliomas. However, to undergo oncogenic events, mature glial 
cells would have to be proliferative and it is currently accepted that most brain cells 
do not divide, during adult life. Thus, numerous recent studies have been suggesting 
that these tumors may arise from the transformation of NPCs or the dedifferentiation 
of mature glial cells in response to genetic alterations (Llaguno et al., 2008).  
The SVZ is one of the most important sources of neural stem/progenitor cells and 
this region is then believed to be in the origin brain tumors. Indeed, many tumors 
develop near this region (Sanai et al., 2005). In addition, corroborating the 
stem/progenitor cell origin of tumors are the similarities shared by normal stem cells 
and tumor stem cells, such as high mobility, extensive self-renewal and proliferation, 
expression of immature profiles and association with blood vessels (Sanai et al., 
2005). Moreover, histological studies demonstrate the lack of the expression of 
differentiated cell markers (Dahlstrand et al., 1992). Finally, Holland and co-workers 
have found that undifferentiated cells may be more sensitive to transformation than 
differentiated cells (Holland et al., 2000). Using a retroviral system, they directed the 
expression of oncogenes to brain cells expressing GFAP or to cells expressing 
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Nestin, and they found that malignant glial tumors arise most efficiently after 
oncogene transfer to nestin-expressing cells. Taken together, these evidences point 
out the involvement of immature precursors cells in the development of the tumor 
phenotype, but it is not known which developmental stage, from NSC to early-
differentiated cell type lineages, are more prone to malignant transformation.  
On the opposite, the existence of cells in the adult brain capable of reverting to a 
less mature state in response to certain stimuli, supports the hypothesis of 
dedifferentiation of mature glial cells (Canoll and Goldman, 2008). These cells were 
known to dedifferentiate into transformed glia with stem cell-like properties through 
retroviral transfection (Bachoo et al., 2002). 
Fig. I.7. – Possible origins of brain tumor stem cells. Brain tumor stem cells (BTSCs) may 
be originated from different cell types and stages. A neural stem cell (NSC) can (1) 
differentiate into a neural progenitor cell or (2) suffer a transformation, originating a BTSC. In 
its turn, the neural progenitor may also (3) differentiate into mature cells (such as neurons, 
astrocytes or oligodendrocytes) or (4) undergo transformation into BTSCs. Notwithstanding, 
mature cells may (5) de-differentiate into neural progenitor, which consequently might (4) 
transform to a BTSC or (6) de-differentiate to a more immature stage (NSC), that still may 
suffer transformation to a BTSC. Adapted from 
http://www.igp.uu.se/Research/Cancer_and_vascular_biology/karin_forsberg_nilsson/?langua
geId=1 
 
 
Thus, if we can identify the cell(s) at the origin of brain tumors, we will be better 
equipped to understand which molecular alterations may lead to cancer, and how we 
can target these by therapeutics or by modulators able to prevent their occurence. 
The cell that is transformed may have important influences on the behaviour of the 
neoplasm and therefore may also affect the patient prognosis. 
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2.2.2. Therapeutic perspectives 
In addition to their relatively quiescence, BTSCs are also resistant to 
chemotherapy due to their enhanced capacity for DNA repair and ABC-transporter 
expression (Atkinson et al., 2009). In fact it was recently described that BTSCs highly 
express Mrp1 (Jin et al., 2010). Besides, these cells have a great infiltrative ability 
and may activate certain survival pathways to inhibit apoptosis (Carmo et al., 2011). 
Thus, new therapies targeting BTSCs may be developed if we want to prevent or 
eliminate recurrent and metastatic disease.  
Molecular analysis of the BTSCs population may lead to the identification of novel 
pathways important for the proliferation, self-renewal and differentiation of these 
cells, oppening new targets for therapy, which should be able to modify the signaling 
pathways or the microenvironment favouring for their self-renewal (Singh et al., 2004; 
Xie, 2009). Yet, another possibility is disrupting the interactions between BTSCs and 
their niche that hopefully will slow tumor bulk malignancy progression can be slowed. 
Also, the promotion of differentiation, particularly if terminally differentiated cells 
types can be generated, may be another useful strategy. 
Due to the infiltrative nature of BTSCs, it is difficult to specifically deliver 
therapeutic agents to these cells. One option it would be to harness the potential of 
normal NCSs, which exhibit strong tropism for brain tumor cells when transplanted 
into the host brain. Thus, intracranial transplantation of NSCs carrying therapeutic 
agent might effectively eliminate BTSCs and inhibit tumor growth (Xie, 2009). 
Efflux pumps, like ABC-drug transporters, may also be targeted it a therapy of 
chemotherapy and adjuvant chemosensitizers could be used with the aim of alter the 
activity of some ABC transporters, leading to better clinical outcomes (Dean et al., 
2005). 
Tumor cells have been found to be in a state of redox imbalance with a more 
oxidizing environment, and show an increased ability to withstand oxidative stress 
(Ogasawara and Zhang, 2009). Recently, several signaling pathways involved in 
different cell processes, such as self-renewal, proliferation and differentiation, have 
been recognized as being under redox regulation (Hernandez-Garcia et al., 2010). In 
fact, some authors have already hypothesized that the highly drug resistance of 
BTSCs can be due to the use of their redox regulatory mechanisms to escape the 
cell death by several anticancer agents (Blum et al. 2009; Hill and Wu, 2009; 
Ogasawara and Zhang, 2009; Boman and Huang, 2008; Morel et al., 2008; Tang et 
al., 2008). Thus, given the significance of redox environment in BTSCs, we can 
hypothesize that molecules with antioxidant potential, such as GUDCA can be used 
as coadjuvants of classical chemotherapy (Szatmari et al., 2006). 
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Thus, potential avenues for therapeutic intervention may require combinations of 
targeted therapies against both stem-like and less tumorigenic cancer cells, as well 
as directed to inhibition of resistance mechanisms in cancer stem cells. The potential 
stem/progenitor glioma origin and the presence of stem-like cancer cells also paves 
the way for new therapeutic avenues such the use of therapy that promotes 
differentiatiom, to retard the growth of malignant astrocytomas. 
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The main goals of the present work are a) to identify novel cues to the cellular 
pathways implicated in gliomagenesis and b) to find a successful adjuvant molecule 
for TMZ therapy that may decrease chemoresistance and/or alter cell environment. 
More specifically, our first aim is to identify which developmental stage, from NSC 
to immature/early differentiated glia, is more susceptible to malignant transformation. 
To accomplish this goal, we will use the mouse glioma cell line GL261, which will be 
first characterized regarding to the expression of neural phenotypes, as well as 
primary cultures of NSC, growing as neurospheres, which will be induced to 
differentiate into astrocytes. Then, we will identify the neural developmental stage 
more similar to glioma cells by comparing the expression of some tumor-related 
markers such as multidrug resistance, angiogenesis potential, autophagy ability, 
migratory and invasion capability.  
In addition, we will also explore the validity of some new molecules as 
coadjuvants in TMZ therapy. Thus, we will evaluate the effect of TMZ, alone in 
association with GUDCA or with MK-571 (an Mrp1 inhibitor) on the viability and 
proliferation of glioma cells, as well as on their cell cycle progression. We will finally, 
explore the effect of GUDCA and MK-571 at the level of some migration-related 
present in of glioma cells. 
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1. Cell cultures  
1.1. GL261 mouse glioma cell line  
The Gl261 was a kind gift from Dr Geza Safrany, from the National Research 
Institute for Radiobiology and Radiohygiene, in Hungary. Cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) (Biochrom AG, Berlin, Germany) 
supplemented with 38.9 mM glucose, 11 mM sodium bicarbonate, 1% 
penicillin/streptomycin and 10% feral bovine serum (FBS) (Invitrogen, Carlsbad, CA, 
USA), at 37ºC and 5% CO2 conditioned atmosphere during 7 days. The medium was 
changed every two days and cells were passaged when the cells reached 
confluence. After 3, 5 and 7 days in vitro, cells plated in coverslips were fixed with 
freshly prepared 4% paraformaldehyde (PFA) (Merck, Darmstadt, Germany) during 
20 min and used for immunocytochemistry assays. The ones that were in the wells 
without coverslips were used for flow cytometry studies or lysed for western blot. 
Growth medium was removed, centrifuged and stored at -80oC to evaluate the 
release of MMPs and S100B.  
 
1.2. Primary neurosphere culture of mouse brain cortex at E15 and induction 
of astrocyte differentiation 
Animal care followed the European Legislation on Protection of Animals Used for 
Experimental and Scientific Purposes (EU directive L0065, 22/07/2003) in order to 
ensure their well-being and minimize animals use and suffering. 
Cortical neural precursors were isolated from embryonic day (E) 15. Briefly, 
pregnant female mice at gestational stage E15 were euthanized by asphyxiation with 
CO2. The fetuses were rapidly decapitated and after removal of meninges and white 
matter, the neocortices were collected in 9 ml of Hank's Balanced Salt Solution 
(HBSS, Invitrogen) and mechanically fragmented. After chemical dissociation with 
trypsin-EDTA 5% (Sigma-Aldrich, St. Louis, MO, USA) and deoxyribonuclease I 
bovine (DNAse I, 1 U/ml, Sigma-Aldrich), the suspension was incubated for 30 min at 
37ºC, with occasional mixing. Following trypsinization, cells were washed three times 
with HBSS and resuspended in 5 ml of RHB-ATM medium (Stem Cell Sciences, 
Cambridge, UK). Once resuspended, cells were mechanically dissociated using a 
Pasteur pipette performing around 20 passages. Approximately 1x106 cells/ml were 
plated into 24-well uncoated tissue culture plates in culture medium supplemented 
with growth factors (10 ng/ml, recombinant murine epidermal growth factor (EGF) 
and basic fibroblast growth factor (bFGF) (PeproTech, Rocky Hill, NK, USA), to form 
free-floating neurospheres, maintained at 37ºC in a humidified atmosphere of 5% 
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CO2, during 48 h. After this period, astroglial differentiation was induced by using 
10% FBS during 7 days. In neurospheres and in cells with 3 and 7 DIV under 
differentiating conditions, cell lysates were collected for western blot analysis and 
their growth medium was removed, centrifuged and stored at -80oC to evaluate the 
release of MMPs and S100B. 
 
2. Characterization of the mouse glioma cell line GL261 
2.1. Characterization of the GL261 cells by immunocytochemistry 
To characterize the glioma cell line, fixed cells were incubated in a 0.1M glycine 
(Merck) solution during 10 min and then permeabilized with 0.1% Triton X-100 
(Roche Diagnostics, Indianapolis, USA) solution for other 10 min. Following three 
rinses with PBS, coverslips were blocked using 10% FBS in Tween 20-Tris buffered 
saline (TBS-T, 0.05% Tween 20, Merck; 20 mM Tris-HCL, 500 mM NaCl, pH 7.5) for 
30 min at room temperature (RT). Coverslips were incubated overnight, at 4°C, with 
anti-microtubule associated protein (MAP)-2 antibody (mouse, 1:100, Millipore, 
Billerica, MA, USA), anti-glial fibrillary acidic protein (GFAP) antibody (rabbit, 1:500, 
Millipore); anti-nestin antibody (mouse, 1:200, Millipore), anti-glutamate transporter 
(GLAST/EAAT1) antibody (mouse, 1:500, AbCam, Cambridge, UK), anti-(sex 
determining region Y)-box 2 (Sox2) antibody (rabbit, 1:500, Millipore) and anti-
vimentin antibody (mouse, 1:25, Santa Cruz Biotechnology, CA, USA). Following 
three rinses with TBS-T, coverslips were incubated with FITC-labelled anti-mouse 
IgG (horse, 1:227, Vector Labs, Burlingame, CA, USA) and Alexa 594-labelled anti-
rabbit IgG (goat, 1:1000, Invitrogen), during 90 min at RT. After rinsed, coverslips 
were incubated with Hoechst dye 33258 (Sigma-Aldrich) during 2 min for cell nuclei 
staining. Following a final rinse in TBS-T and dehydration with methanol (Merck), 
coverslips were mounted using DPX (BDH Prolabo, Bangkok, Thailand) and stored 
at 4°C. Finally pairs of U.V. and fluorescence images of ten random microscopic 
fields (original magnification: 252x) were acquired per sample. Immune-positive cells 
for each cell type and total cells were counted to determine the percentage of 
positive nuclei. The resultant values were presented as percentage of positive cells 
for each staining.  
 
2.2. Characterization of the GL261 cells by flow cytometry 
To characterize the glioma cell line by flow cytometry, cells were trypsinized with 
0,1% Trypsin-EDTA in PBS and collected. Then cells were centrifuged at 500 g for 5 
min at 4ºC and washed once with Phosphate buffered saline (PBS). After that, cells 
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were fixed with 4% PFA for 20 min in ice and centrifuged. Cells were blocked using 
10% FBS TBS-T for 20 min at RT. Following centrifugation, cells were incubated 
during 30 min at RT, with the antibodies mentioned in section 4.2. Cells were 
incubated with FITC-labelled anti-mouse IgG (1:227) and Alexa 594-labelled anti-
rabbit IgG (1:1000), during 30 min at RT. After centrifugation, cells were rinsed once 
and ressuspended in PBS. Finally, cellular suspension was plated in a 96-wells plate 
and analysed by flow cytometry (Guava – Easy Cyte HT model, Millipore). Results 
were expressed as percentage of positive cells for each one of the antibodies 
analyzed. 
 
3. Charaterization of tumor-related factors 
3.1. MMPs activity 
To compare the activity of MMPs of the GL261 cell line and with each of the 
neural developmental stages, aliquots of glioma cells supernatants (3, 5 and 7 DIV), 
NSC and differentiating astrocytes at 3 and 7 DIV were analyzed by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography in 0.1% 
gelatin/10% acrylamide (Sigma-Aldrich; Merck) gels under non-reducing conditions. 
After electrophoresis, gels were washed for 1 h with 2.5% Triton X-100 (in 50 mM 
Tris pH7.4; 5 mM CaCl2; 1μM ZnCl2) to remove SDS (VWR-Prolabo) and renature 
the MMPs species in the gel. Then the gels were incubated in the developing buffer 
(50 mM Tris pH7.4; 5 mM CaCl2; 1μM ZnCl2) overnight to induce gelatine lysis. For 
enzyme activity analysis, the gels were stained with 0.5% Coomassie Brilliant Blue 
R-250 (Sigma-Aldrich) and destained in 30% ethanol/10% acetic acid/H2O. 
Gelatinase activity, detected as a white band on a blue background, was quantified 
by computerized image analysis and normalized with total cellular protein. 
 
3.2. S100B assay 
The expression of S100B in glioma cells (at 3, 5 and 7 DIV), NSC and 
differentiating astrocytes at 3 and 7 DIV was assessed by ELISA. Supernatants were 
incubated with monoclonal antibody anti-S100B (1:1000, Sigma-Aldrich) in 
carbonate-bicarbonate buffer (50mM, pH 9.5) per well at 4oC overnight. After three 
washes with wash buffer (0.1% bovine serum albumin (BSA, Sigma-Aldrich) and 
0.05% Tween(Merck)), supernants were blocked (2% BSA in PBS) for 1 h at RT. To 
each sample was added 50mM Tris buffer (pH 8.6, with 0.2mM CaCl2), followed by 
three washes with wash buffer. Supernants were incubated with polyclonal antibody 
anti-S100 (1:5000 in 0.5% BSA with 0.2 mM Cacl2 in PBS, Dako, Dernmark, A/S) for 
30 min at 37oC and, then, incubated with antibody anti-rabbit peroxidase conjugated 
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(1:5000 in 0.5% BSA in PBS, Santa Cruz Biotechnology) under same conditions. 
Following washes with both wash buffer and PBS, it was added substract solution 
(Sigma Fast OPD in H2O, Sigma-Aldrich) for 30 min at RT and under light protecting. 
At last, absorbance was measured at 450 nm. 
 
3.3. Expression of tumor-associated factors  
To compare some tumor-associated factors of the GL261 cell line with the 
different neural developmental stages, total cell extracts of both glioma cells (3, 5 
and 7 DIV), NSC and differentiating astrocytes at 3 and 7 DIV, were obtained by 
lysing cells in ice-cold Cell Lysis Buffer (Cell Signaling, Beverly, MA, USA) plus 1 mM 
phenylmethylsulfonyl fluoride (PMSF, Sigma-Aldrich) for 10 min, on ice, followed by 
sonication. The lysate was centrifuged at 14 000 g for 10 min, at 4ºC, and the 
supernatants were collected and stored at -80ºC. Protein concentrations were 
determined using the Bradford assay. Equal amounts of protein were subjected to 
SDS-PAGE and transferred to a nitrocellulose membrane (Amersham Biosciences, 
Piscataway, NJ, USA). After transfer, blotted membranes were blocked for 1 hour at 
RT with 4% milk in TBS-T (in case of Mrp1 expression evaluation) and in 5% BSA 
(Sigma-Aldrich) in TBS-T (for determination of VEGF, β-actin and LC3) and 
incubated overnight at 4ºC with anti- multidrug resistance protein 1 (Mrp1)-A23 
antibody (1:750, Sigma-Aldrich), anti-vascular endothelial growth factor (VEGF) 
antibody (1:200, Santa Cruz Biotechnology), anti-β-actin antibody (1:5000, Sigma-
Aldrich) and anti-protein light chain 3 (LC3) antibody (1:2000, Cell Signaling) in 
respective blocking solution. After washing with TBS-T, the membranes were 
incubated with secondary antibody anti-rabbit (horse, 1:5000, Santa Cruz 
Biotechnology) or anti-mouse (goat, 1: 5000, Amersham Biosciences), as 
appropriate, in blocking buffer for 1 h, at RT. After washing membranes with TBS-T, 
chemiluminescent detection was performed by LumiGLO® (Cell Signaling) and 
bands were visualized by autoradiography with Hyperfilm ECL. The relative 
intensities of protein bands were analyzed using the Quantity one® 1-D 
densitometric analysis software (Bio-Rad, Hercules, CA, USA). 
 
4. Cell treatments  
Glioma cells were first treated (or untreated, control) with TMZ (50, 100 and 250 
µM, Sigma-Aldrich) during 24, 48 and 72 h. After incubation, cell viability was 
evaluated in order to ascertain the most efficient TMZ incubation conditions to be 
subsequently used. After this first trial, glioma cells were then incubated with TMZ 
alone or in the presence of MK-571 (25 µM, Sigma-Aldrich), or GUDCA (50 µM, 
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Calbiochem Darmstadt, Germany) at selected exposure conditions. After incubation, 
it was determined the cell viability, proliferation, cell cycle progression and cell death 
by apoptosis. The success of GUDCA or MK-571 co-incubation was evaluated by 
comparing the results with those obtained with TMZ alone.  
Glioma cells with 3, 5 and 7 DIV were also incubated with MK-571 (25 µM), or 
GUDCA (50 µM) at the previously selected exposure time, to explore the effect of 
these molecules on some migration-related factors of glioma cells, such as CXCR4 
expression. 
 
4.1. Cell viability  
Cell viability was determined by evaluating [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium] (MTS) reduction in the 
presence of phenazine methosulfate (PMS), which forms a formazan product that is 
released to the culture medium, with an absorbance maximum at 490 nm. 
A combined MTS/PMS solution (1:20, with stock solution at 2 mg/ml and at 0.92 
mg/ml, respectively) was freshly prepared and after the cell treatment, supernatants 
were removed and cells incubated for 45 min, at 37°C, in a dilution of 1:10 in culture 
medium. At the end of incubation, the absorbance of the medium was read at 490 
nm using an ELISA plate reader. 
 
4.2. Cell cycle progression  
For determination of cell cycle progression, the cells were analyzed by flow 
cytometry. At the end of incubation period, cells were collected, washed with PBS, 
centrifuged at 500 g for 10 min, and then the pellet was resuspended in a fixative 
solution with glycine:ethanol (3:7, volume/volume) solution for 30 min at 4ºC. After 
centrifugation at 500 g for 10 min, cells were washed with PBS and the pellet 
resuspended and incubated for 10 min in the dark, at RT, in a solution of PBS 
containing 10μL/mL propidium iodide (PI, Invitrogen, Paisley, UK) and 10μL/mL 
RNAse. The PI fluorescence was measured on a FACScan flow cytometer (BD 
FACSCaliburTM) and the data were gated to exclude cell debris and aggregates. 
 
4.3. Expression of CXCR4 
To evaluate CXCR4 expression, total cell extracts of GL261 cells (3, 5 and 7 DIV) 
were obtained by lysing cells in ice-cold Cell Lysis Buffer plus 1 mM 
phenylmethylsulfonyl fluoride (PMSF) for 10 min, on ice, followed by sonication. The 
lysate was centrifuged at 14 000 g for 10 min, at 4ºC, and the supernatants were 
collected and stored at -80ºC. Protein concentrations were determined using the 
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Bradford assay. Equal amounts of protein were subjected to SDS-PAGE and 
transferred to a nitrocellulose membrane. After transfer, blotted membranes were 
blocked for 1 h at RT in 5% milk TBS-T and incubated overnight at 4ºC with anti-
CXCR4 antibody (rabbit, 1:1000, AbCam), and anti-β-actin antibody (1:5000) in 
respective blocking solution. After washing with TBS-T, the membranes were 
incubated with secondary antibody anti-rabbit (1:5000) or anti-mouse (1: 5000), as 
appropriate, in blocking buffer for 1 h, at RT. After washing membranes with TBS-T, 
chemiluminescent detection was performed by LumiGLO® and bands were 
visualized by autoradiography with Hyperfilm ECL. The relative intensities of protein 
bands were analyzed using the Quantity one® 1-D densitometric analysis software 
(Bio-Rad, Hercules, CA, USA). 
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1. Characterization of the mouse glioma cell line GL261 
In this Chapter of Results we have decided to continuously evaluate and 
moderately discuss the significance of the values obtained to better understand the 
relevance of the values achieved in each point, due to the novelty of the approach 
we have programmed to follow. 
 The application of suitable experimental models to glioma research, which 
ideally should harbor key features of the human disease, is necessary for the 
identification of more specific targets and development of novel and target-directed 
therapies. One of the most widely used for preclinical and translational research is 
glioma 261 (GL261) cell line (Wu et al., 2008). These cells carry point mutations in 
the K-ras and p53 genes (Szatmari et al., 2006) and exhibit, as other glioma cell 
lines, populations of cells that have characteristics of cancer stem cells, such as the 
CD133+ cells (Wu et al., 2008), as well as a sub-population of cells more sensitive to 
ATP (Tamajusuku et al., 2010). The choice of the GL261 cell line, instead of the 
other currently used cell line C6 derived from rat glioma cells and representing 
astrocyte-like cells (Swarnkar et al., 2012), was  based on data evidencing that C6 
gliomas are slightly invasive and only induce moderate vascular alterations, whereas 
GL261 tumors dramatically alter the brain vessels in the glioma region (Doblas et al., 
2010), a property that we were interested to explore in the present work. Moreover, 
GL261 cells were recently considered, between several tested rodent glioma models, 
the one showing the greatest alterations in glioma metabolites (e.g. glutamate, 
lactate, total choline and creatine, glutamine-, aspartate, guanosine, mobile lipids 
and macromolecules, among others) (Doblas et al., 2012). 
To assess the different stages of differentiation and the several cell types that 
may constitute the GL261 cell line, we started by using specific antibodies against 
proteins that are characteristic of undifferentiated and differentiated cells, at three 
different time points – 3 days in vitro, 5DIV and 7DIV. In order to characterize and 
evaluate the content in undifferentiated proliferating cells, it was used antibodies 
against Nestin and Sox2. Vimentin was used to stain early astrocyte progenitors and 
antibodies against βIII-Tubulin and MAP2 to identify neuronal cells. The astrocytic 
population was evaluated through the use of antibodies specific for GFAP and 
GLAST. 
Initially, the characterization was performed by using immunocytochemistry 
(Fig.IV.1A.). We have observed that although all glioma cells were positive to the 
antibodies tested, it can be observed a different staining pattern. In fact, it seems that 
the markers more related to differentiated cells, such as GFAP and MAP2, were 
particularly evident in the cytoplasm and thus we can clearly visualize cell 
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ramifications, while GLAST is located near nuclei. The markers more related to 
undifferentiation, such as Nestin and Vimentin, stained cytoskeleton, whereas Sox2 
labeled the perinuclear zone. However, this method enabled us to more accurately 
quantify the different phenotypes of GL261 cells along the time in culture, since all 
the cells were labeled. 
Thus, the characterization proceeded by using the flow cytometry. This method is 
often used, not only for being a faster one, but also because of its higher specificity. 
The evaluations were optimized and the data obtained by flow cytometry confirmed 
that, in fact, the cellular composition of the GL261 cell line was not the same along 
the culture time window.  
As shown in Fig. IV.1B, and despite only one assay has been performed, it can 
be observed that the expression of Vimentin increased 15,2% from 3 to 5 DIV and 
then remained constant until 7DIV, whereas the expression of both Sox2 and βIII-
Tubulin decreased from 3 to 7 DIV, the decrease was more marked for Sox2 (40%) 
than for βIII-tubulin (23%). Because Sox2 is a glioma stem cell marker (Allen et al., 
2012) data indicate that the stem cell representation in the GL261 cell line declines 
significantly and continuously (Fig. IV.1B) along the time in culture. Being Sox2 an 
undifferentiated cell marker, we can speculate that the early GL261 3DIV, may 
correspond to a more stem cell-like population and thus, with higher proliferation 
ability. In fact, undifferentiated phenotypes, this is, stemness phenotypes, have been 
associated to self-renewal capacity with implications toward possible roles in brain 
tumorigenesis (Shiras et al., 2003; Gangemi et al., 2009). Gangemi et al have 
denoted that Sox2 silencing in GBM cancer stem cells drive to proliferation inhibition 
and the loss of the tumorigenicity in immunodeficient mice, demonstrating the 
fundamental role for maintenance of the self-renewal capacity of neural stem cells 
when they have acquired cancer properties. Therefore, it is speculated that SOX2, or 
its immediate downstream effectors, would then be an ideal target for glioblastoma 
therapy. 
βIII-tubulin is a neuronal differentiation marker aberrantly expressed in astrocytic 
gliomas (Katsetos et al., 2003) and linked to malignant changes in glial cells 
(Katsetos et al., 2007). Its overexpression has been related with chemoresistance 
(Zheng et al., 2012) and accumulation of βIII-tubulin was observed around the G2/M 
stage of the cell cycle of tumor cells (Shibazaki et al., 2012). The increased 
expression of βIII-tubulin in GL261 cells asserts, thus, a link between its aberrant 
expression and a disruption of microtubule dynamics usually observed during the 
transformation of a low-grade to a high-grade glioblastoma (Katsetos et al., 2011). 
Therefore, we may assume that GL261 even at 7DIV differentiation still have glioma 
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tumorigenesis, tumor progression and malignant transformation characteristics of 
glioblastoma multiform (Katsetos et al., 2009).  
Vimentin, a mesenchymal marker (Ma et al., 2012), is a primordial component of 
the cytoskeleton and the nuclear envelope (Wang et al., 2010) that has been used as 
a molecular marker for glioblastoma multiform and astrocytoma (Yang et al., 1994; 
Mennel and Lell, 2005). The increase in Vimentin at both 5 and 7DIV (Fig. IV.1B) 
may result from increased cell migration abilities as its up-regulation is associated 
with tumor invasiveness (Jan et al., 2010; Thakkar et al., 2011).  
GFAP is widely expressed in astroglial cells, neural stem cells, astroglial tumours, 
such as glioblastoma. It is consider a diagnostic marker of glioblastoma multiforme 
because GFAP presence is associated with more aggressive and invasive potentials 
(Jung et al., 2007). These authors observed that the most uniform GFAP staining 
was in well-differentiated grade II astrocytomas. We found that the expression of 
GFAP was almost the same along the time in culture (~70% of positive cells), with a 
10% decrease at 7DIV. Once GFAP expression is related to the differentiation status 
of astrocytes (Jung et al., 2007) we can hypothesize that cell proliferation in our case 
is not so much elevated. Interestingly, many high-grade gliomas also seem to lose 
GFAP expression (Jacque et al., 1978; van der Meulen et al., 1978; Jacque et al., 
1979; Velasco et al., 1980; Tascos et al., 1982) (Rutka et al., 1997). In addition, 
GFAP-negative cells proliferate more rapidly than GFAP-positive cells in the same 
tumor (Hara et al., 1991; Kajiwara et al., 1992). These in vivo findings allow 
demonstrate that the loss of GFAP expression could represent secondary loss of a 
differentiation marker or alternatively, it could be a step in tumor development 
(Wilhelmsson et al., 2003). Thus, we may speculate that GL261 at 7DIV have 
increased its aggressiveness and invasive potentials in comparison to 3DIV cells.  
Finally, GLAST and MAP2 are expressed unevenly, with increased levels at 5 
DIV. GLAST is an astroglial glutamate transporter that was shown to be present in 
glioma cells (Baber and Haghighat, 2010) at similar levels to those of astrocytes, 
although its mislocation was noticed as an intrinsic feature of glioma cells  (Ye et al., 
1999). Variations in the Wnt-1 oncogene expression (Palos et al., 1999; Jimenez et 
al., 2003) may be in the origin of the observed GLAST fluctuation between GL261 
from 3 to 7DIV, and deserve to be evaluated in the future.  
MAP2 is another early neuronal marker that was shown to be also present in 
glioma cell lines and biopsies (Yan et al., 2011). In fact, MAP2 expression was 
demonstrated to occur transiently in migrating immature glial cells and indicated as 
corroborating the glial origin of the gliomas (Blumcke et al., 2001). 
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B) 
 
 
Fig. IV.1. Characterization of the glioma cell line GL261. Glioma cells were maintained in DMEM 
supplemented with 1% PenStrep and 10% FBS as previously described in Methods. Cells were fixed at 
3, 5 and 7 days in vitro and processed for immunocytochemistry (A), where nuclei were stained with 
Hoechst dye (blue), or toflow cytometry analysis (B). Representative images (A) and data obtained from 
a single independent experiment (B). GFAP, glial fibrillary acidic protein, GLAST, glutamate aspartate 
transporter, MAP2, microtubule-associated protein 2. Scale bar: 20 μm. 
 
Overall, these results indicate that the sub-fractions of cells that constitute the 
GL261 cell line and attest the tumor heterogeneity feature (Deleyrolle et al., 2012) 
change in accordance with the time of cells in culture. Also, indicate that 
independently of the time in culture these cells exhibit a primary tumor phenotype 
and highlight their value to explore the origin of gliomas and for preclinical modeling 
of novel anti-glioblastoma therapeutic agents. However, taking in account the results 
of a sole experiment, careful should be taken in the appreciation of the results just 
presented, and new series should be undertaken in the near future to validate them.  
In the next section, we decided to compare some important biological glioma like 
properties of GL261 cells at the 3 different culture temporal windows with 3 steps of 
neural precursors cell differentiation. 
 
2. Characterization of common features between GL261 glioma cells and 
differentiating astrocytes from neural stem cells 
NSCs, due to their longevity, self-renewal, high motility and sustained 
proliferative capacity, are believed to be in the origin of the glioma (Ignatova et al., 
2002; Sanai et al., 2005) and their pluripotency the cause of the cellular diversity of 
the tumor (Tan et al., 2006; Louis et al., 2007). Therefore, it is plausible that in a 
particular point of NSC differentiation they are at an increased risk for malignant 
transformation.  This risk may be associated with a phenotype that will most 
resemble equivalent one in glioma cells. To explore this resemblance, we 
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characterized and compared some features associated to brain tumors, in glioma 
cells, as well as on primary cultures of NSC, growing as neurospheres, which were 
induced to differentiate into astrocytes. This way, we propose to identify the neural 
developmental stage more similar to glioma cells by comparing the expression of 
some tumor-related factors such as multidrug resistance, angiogenesis potential, 
autophagy ability and invasion capability. 
 
2.1. Invasion ability 
One of the most important characteristics of tumor cells is their ability to invade 
the surrounding tissue. This feature is associated to the presence of proteins, like 
MMPs and S100B. 
Interestingly, the activity of MMPs, both MMP-2 and MMP-9, decreased along the 
different time points in GL261, reaching very low values at 7DIV (0.3- and 0.2- fold 
vs. GL261 3DIV p<0.01, respectively). The activity of these gelatinases increased 
from neurospheres to 3 and 7 DIV, thus approaching the levels observed at GL261 
3DIV. Conversely, the value obtained in neurospheres was close from the one 
observed in GL261 at 5 and 7DIV. Thus, it seems that Sox2 and βIII-tubulin, which 
were more expressed at GL261 at 3DIV may be related with an increased MMP 
expression and mobility. Intriguingly, in a recent study Oppel et al. (Oppel et al., 
2011) reported that the knockdown of Sox2 impaired the invasive proteolysis-
dependent migration of glioma cells also reducing the expression level of pro-MMP1 
and pro-MMP2, and that Sox2 plays a role in the maintenance of a less differentiated 
glioma cell phenotype. In addition, silencing of MMP-2 evidenced to reduce stem cell 
migration and tropism towards the tumor cells (Bhoopathi et al., 2011). Further, the 
expression of active MMP-2 and MMP-9 was indicated to enhance with the growth of 
malignant gliomas (Zhao et al., 2007) and their down-regulation evidenced to reduce 
glioma stem cell proliferation (Reddy et al., 2011) and invasion (Annabi et al., 2008; 
Silveira Correa et al., 2010). To emphasize that βIII-tubulin positive immunoreactivity, 
although less documented, was also related with a cell active migration (Katsetos et 
al., 1998). Finally, based on these results we can speculate that GL261 3DIV and 3 
and 7DIV differentiating astrocytes are those with most invasive ability.  
The release of S100B into the extracellular medium revealed to increase with the 
time in culture, with the highest values in both GL261 and differentiating astrocytes at 
7DIV (Fig. IV.3). S100 proteins are known to be involved in proliferation, 
differentiation and migration/invasion among other aspects (Donato et al., 2012). A 
recent study demonstrated that the transfection of S100B promotes cell invasion and 
migration and can be related with the development of brain metastasis (Pang et al., 
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2012). However, the majority of the data published were related with the invasion 
property of lung cancer cells in the brain (Hu et al., 2010; Jiang et al., 2011). 
 
 
A) 
 
 
 
 
B)  
 
 
 
 
 
 
 
 
 
Fig. IV.2. Metalloproteinase (MMP)-2 and MMP-9 activities in GL261 glioma cells at 3, 5 and 7 
days in vitro and in differentiating astrocytes from neurospheres (NS) during 3 and 7 DIV. Cells 
were cultured as indicated in methods. Cell supernatants were collected for quantification of MMP 
activity. A) MMP-2 and MMP-9 were identified by their apparent molecular mass of 72 and 92 kDa, 
respectively. Representative results from one experiment are shown. B) Graph bars represent the 
intensity of the bands that were quantified by scanning densitometry, standardized to respective protein 
quantification and expressed as mean ± SEM from at least three independent experiments. Results are 
and presented as fold change compared to GL261 3DIV (considered as 1). Data obtained from at least 
three independent experiments. **p<0.01 and *p<0.05 vs. GL261 3DIV; 
##
p<0.01 and 
#
p<0.05 vs.. 
GL261 5DIV; 
§§
p<0.01 and 
 §
p<0.05 vs. GL261 7DIV.  
 
Concentrations in glioma cells (~0.5 to 7 μM, from 3DIV to 7DIV) are several 
times higher than in neurospheres (~0.1 nM) or differentiating astrocytes (~0.2 µM), 
thus indicating a substantial difference between both types of cells, that surely 
deserves further investigation. Correspondingly, it is described that at nanomolar 
concentrations, as the ones observed in neurospheres, S100B exerts neurotrophic 
properties for normal brain development (Rothermundt et al., 2003). The increase of 
S100B during the astrocyte differentiation process may be related to the fact that 
S100B expression also characterizes a terminal maturation stage of cortical 
astrocytes, since astrocytes do express S100B in the mature nervous system (Brozzi 
et al., 2009).  Contrastingly, at micromolar concentrations, similar to the ones found 
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in our glioma cells, S100B could be participate in the pathophysiology of some brain 
diseases, including brain cancer. These concentrations, revealed to increase cellular 
proliferation (Leclerc et al., 2007) and Brozzi et al. (Brozzi et al., 2009) suggested 
that S100B may contribute to reduce the differentiation potential of cells of the 
astrocytic lineage, beyond the contribution to enhance migration capability, suggests 
that this protein might contribute to maintaining a neoplastic, invasive phenotype. In 
fact, Vos et al related high levels of S100B with shorter survival in a relatively high 
proportion of patients with GBM (Vos et al., 2004).  
 
 
 
 
 
 
 
 
 
 
Fig. IV.3. S100B release from GL261 glioma cells at 3, 5 and 7 days in vitro and in differentiating 
astrocytes from neurospheres (NS) during 3 and 7 DIV. Cells were cultured as indicated in methods. 
The conditioned media was collected, and S100B released into the medium was determined by ELISA, 
with monoclonal antibody anti-S100B. Quantitative analysis of S100B release was expressed as fold 
increase vs. GL261 3DIV (considered as 1); **p<0.01 and **p<0.05 vs. the GL261 3DIV; 
#
p<0.05 vs. 
GL261 5DIV; 
§
p<0.05 vs. GL261 7DIV.  
 
Overall, when comparing these developmental phenotypes to glioma cells, the 
most close to GL261 3DIV are the differentiating astrocytes, regardless the 
concentration values be significantly different, as it was also observed for MMPs. 
 
2.2. Angiogenesis 
Glioblastoma is characterized by its capacity to induce neovascularization, driving 
continued tumor growth, due to its high content in VEGF and autocrine signaling (Lee 
et al., 2011). As previously referred, angiogenesis might be triggered and enhanced 
by the release of VEGF, which is a protein regulated by hypoxia through HIF-1. In 
Fig. IV.4, a decrease in VEGF expression during the time in culture was noticed in 
both glioma cells and astrocytes differentiated from neurospheres. In the first case, 
there was a 50% reduction from GL261 at 3 DIV to 5 DIV (p<0.01). Similar 
expression was also observed in neurospheres and differentiating astrocytes at 3 
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DIV, followed by a decrease at 7 DIV (i.e. a change from 0.6- to 0.3-fold, p<0.01). 
However, it should be emphasized that these results correspond to two experiments 
(n=2) and thus, further data should be acquired in order to corroborate these 
observations, also using GL261 cells with 7 DIV. 
 
A)  
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
Fig. IV.4. VEGF expression in GL261 glioma cells at 3, 5 and 7 days in vitro and in differentiating 
astrocytes from neurospheres (NS) during 3 and 7 DIV. Cells were cultured as indicated in methods. 
Total cell lysates were subjected to SDS-PAGE followed by Western blotting with antibody specific for 
VEGF. A) Representative results from one experiment are shown. B) Graph bars represent the intensity 
of the bands, which was quantified by scanning densitometry, standardized with respect to β-actin 
protein and expressed as mean ± SEM fold change compared to glioma cells. The values indicate the 
fold change obtained when compared with GL261 at 3DIV (considered as 1). **p<0.01 vs. GL261 3DIV. 
 
Interestingly, it was recently observed by immunohistochemistry that the 
percentages of tumors expressing VEGF (96%) and MMP-9 (75%) are in the glioma 
high-grade group, exhibiting higher levels than in the low-grade group (67% and 
24%, respectively) and correlated to the invasion of glioma (Liu et al., 2011). Our 
results evidence the higher malignancy of GL261 at 3DIV with equivalent increased 
values of MMP-9 (see Fig. IV.2). Moreover, it deserves to be noted that both 
neurospheres and differentiating astrocytes at 3 DIV still contain elevated levels of 
VEGF and similar to those presented by GL261 cells at 5 DIV, thus evidencing a 
close affinity.  Elevated expression of VEGF in NSCs has been documented and it 
has been unveiled an intrinsic relationship between angiogenesis and NSC, where 
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up-regulation of VEGF lead to the increase of Nestin positive cells (Mani et al 2005, 
Sun et al 210). Moreover, inhibition of the VEGF signaling was shown to reduce the 
migration and to induce differentiation (Kaus et al., 2010; Joo et al., 2012). 
 
2.3. Multidrug resistance 
The drug resistance of tumors is one of the main causes to treatment fail and to 
the progress of the disease over the years. There are diverse reasons why tumor 
cells can resist to chemotherapeutic drugs, and the transporter Mrp1 is one of them. 
Mrp1 revealed to be significantly up-regulated in cancer stem-like cells (Jin et al., 
2008) and in CD133+ human brain glioma stem cells (Bi et al., 2007), besides being 
more expressed in the high grade glioma (Calatozzolo et al., 2012), reason why it 
has been suggested that chemosensitization of cells with Mrp1 inhibitors may favor 
the treatment of gliomas (Peignan et al., 2011). 
 
A) 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
Fig. IV.5.  Mrp1 expression in GL261 glioma cells at 3, 5 and 7 days in vitro and in differentiating 
astrocytes from neurospheres (NS) during 3 and 7 DIV.). Cells were cultured as indicated in 
methods. Total cell lysates were subjected to SDS-PAGE followed by Western blotting with antibody 
specific for Mrp1. A) Representative results from one experiment are shown. B) Graph bars represent 
the intensity of the bands quantified by scanning densitometry, standardized with respect to β-actin 
protein and expressed as mean ± SEM fold change compared to glioma cells, from at least 3 
experiments. The values indicate the fold change obtained when compared with GL261 at 3DIV (taken 
as 1). **p<0.01 vs. GL261 3DIV; 
##
p<0.01 and 
#
p<0.05 vs. GL261 5DIV.  
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The results of the analysis of Mrp1 expression depicted in Fig. IV.5. show that 
despite the existence of a 1.3-fold increase from day 3 to day 5 of glioma cells 
(p<0.01), there is an unexpected marked decrease from 5 to 7 DIV (0.2-fold vs. 
GL261 3DIV, p<0.01). Moreover, results obtained in neurospheres were those 
presenting a higher similarity to GL261 cells at both 3 and 5 DIV. However, we can 
also consider that a matched correspondence still exist between GL261 at 7 DIV and 
astrocytes in differentiation from NS, although with significant lower levels of Mrp1 
(decline to 0.3- and 0.5-fold) that the first group above mentioned.  
Overall, it seems that the increased values of Mrp1 are associated with 
greater cell proliferation ability, as other ongoing studies also suggest. Further 
studies on Mrp1 should include the evaluation of Mrp1 activity (Lee et al., 2012), in 
order to investigate if an increased expression of this protein is related with a higher 
ability to make the efflux of some drugs, and thus, to an increased chemoresistance. 
As this multidrug resistance phenomenon is considered to be the major barrier to 
patient survival, a chemotherapeutic scheme that include Mrp1 modulators, may be 
imperative to overcome the conventional drug resistance in patients with relapsed 
GBM. 
 
2.4. Autophagy 
Autophagy is a process that promotes sequester and degradation of bulk 
cytosolic proteins and damaged organelles by the lysosome. It has been shown that 
some drugs used in chemotherapy may activate autophagy instead of apoptosis in 
malignant glioma cells (Kanzawa et al., 2004). Therefore, the expression of LC3, one 
of the autophagosome-membrane proteins, was analyzed. Autophagic activity can be 
analyzed by Western blot through by the ratio of lapidated LC3-II that studs the inner 
and outer autophagosoma membrane to unmodified LC3-I. 
The results depicted in Fig. IV.6 show that LC3 is constitutively expressed in all 
cell types, GL261, NS and differentiating astrocytes. Due to limitation of time and 
some identification band problems only data from one experiment are shown. 
Nevertheless, there is indication that LC3 lipidation increase along differentiation 
of astrocytes from neurospheres, which showed the lowest levels. Autophagic activity 
in differentiating astrocytes evidenced a 1.3-fold increase when compared to GL261 
5DIV. This is not without precedent once the autophagic activity in glioma 
stem/progenitor cells was shown to be significantly lower than that in neural 
stem/progenitor cells. However, the autophagic activity markedly increased if glioma 
stem/progenitor cells are induced to differentiate by fetal calf serum (Zhao et al., 
2010). 
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A) 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
Fig. IV.6. LC3II/I expression in glioma cells at 5 days in vitro and in differentiating astrocytes 
from neurospheres (NS) during 3 and 7 DIV. Cells were cultured as indicated in methods.  Total cell 
lysates were analyzed by Western blotting with antibody specific for LC3 and then quantified and treated 
as described before. A) Representative results from one experiment are shown. B) Graph bars 
represent the values indicating the density proportion of each protein compared with GL261 5DIV (taken 
as 1). Results are from one experiment. 
 
Nevertheless further data should be obtained, as these results were acquired 
from one single experiment, and also it should be used the missing GL261 at 3 and 7 
DIV, in order to look for the effect of the time in culture on this cell property, based on 
the findings above indicated. Enhanced LC3-II/LC3-I expression in differentiating 
astrocytes from neurospheres is in agreement with other studies suggesting that 
neural stem/progenitor cells activate autophagy to fulfill their high energy demands 
(Vazquez et al., 2012). Autophagy was similarly indicated to play an essential role in 
the regulation of self-renewal, differentiation, tumorigenic potential and 
radiosensitization of glioma-initiating cells. Moreover, it is suggested that induction of 
autophagy promotes the differentiation of these cells and their susceptibily to 
radiotherapy (Zhuang et al., 2011; Palumbo et al., 2012; Teres et al., 2012). 
However, it deserves to be noted that CD133+ glioblastoma cells, considered as a 
small fraction of cells with features of primitive neural progenitor cells and tumor-
initiating function in brain tumors, show defective autophagy, which probably relates 
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with their resistance to TMZ (Fu et al., 2009). Thus, we may considerer that this 
important glioma subpopulation should be a target to combined therapy using TMZ 
and inducers of this signaling pathway, in order to improve the survival of patients 
with glioma. Nevertheless, caution should also be undertaken as other studies have 
revealed that the inhibition of autophagy favors TMZ-induced apoptosis in glioma 
cells, and that agents targeting mitochondria or endoplasmic reticulum may be 
potential anticancer strategies (Lin et al., 2012). This is a very controversial subject 
deserving clarification. 
 
3. Effects of a combined anticancer strategy on GL261 cell viability and 
cell cycle 
Despite the new insights into the molecular pathogenesis of glioblastoma, several 
aspects are not full elucidated and treatments fail to cure the majority of patients. 
With standard therapy, which consists of surgical resection with concomitant TMZ in 
addition to radiotherapy followed by adjuvant TMZ, the median duration of survival is 
12-14 months. Therefore, therapeutic schemes clearly deserve to be improved, and 
novel molecular targets and inhibitory agents has become a focus of research for 
glioblastoma treatment. Thus, the second main objective of this thesis was to find a 
successful adjuvant molecule for TMZ therapy that would enhance TMZ therapeutics 
potential. For that we started to evaluate the effect of TMZ in GL261 cell line, at the 
cell viability and cell cycle levels, followed by the analysis of conjoint association 
effects of some other molecules, such as GUDCA and an Mrp1 inhibitor, the MK-571. 
 
3.1.  Effect of TMZ on glioma cells viability 
GL261 glioma cells were treated (or untreated, control) with TMZ (50, 100 and 
250 µM) during 24, 48 and 72 h. After incubation, cell viability was evaluated by the 
MTS assay, in order to determine the most efficient TMZ incubation conditions to be 
subsequently used in the following studies. We have observed that TMZ treatment 
induced a significant decrease in glioma cells viability, which occurred in a dose- and 
time-dependent manner (Fig. IV.7.). Thus, the effect of TMZ was particularly evident 
at the highest TMZ concentration, with an incubation period of 72 h. At these 
conditions, TMZ 250 µM was able to induce a 40% decrease on cell viability (p<0.05) 
as compared to the respective control cells. 
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Fig. IV.7. Effect of temozolomide (TMZ) addition in glioma cells viability. Glioma cells were 
incubated with crescent concentrations of TMZ (50, 100 e 250 μM) during three different incubation 
periods (24, 48 and 72 h). Cell proliferation was determined by evaluating [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) reduction in the presence of 
phenazine methosulfate (PMS), and absorbance of the medium was then red at 490 nm. Data are 
expressed as percentage ± SEM of the value obtained for the control at each incubation period. 
**p<0.01 and *p<0.05 vs. control. 
 
Based on the results achieved we selected to the following assays a TMZ 
concentration of 250 µM, and the lowest and the highest incubation periods (24 and 
72 h), to easily compare the effects produced by the combined therapy. 
 
 
3.2. Effect of TMZ, GUDCA and TMZ+GUDCA on glioma cells viability and 
cell cycle 
It was recently demonstrated that TMZ-treated glioma cells undergo ROS/ERK-
mediated apoptosis and autophagy, during which autophagy serves to protect glioma 
cells from TMZ-induced apoptosis. Furthermore, resveratrol, an antioxidant molecule, 
augments the effect of TMZ by reducing autophagy and increasing apoptosis both in 
vitro and in vivo (Lin et al., 2012). Overall, those studies suggested that the 
administration of resveratrol combined with TMZ could be a potential treatment 
strategy for patients with brain tumors. Therefore, we sought that was also very 
interesting to explore if the antioxidant GUDCA, a molecule with anti-proliferative, 
anti-apoptotic and anti-inflammatory properties (Akare et al., 2006), which has 
already been shown to prevent colon tumorigenesis (Wali et al., 2002), could also be 
a successful adjuvant molecule for TMZ therapy. 
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After the first trial for the conditions to be used, GL261 were then incubated with 
TMZ alone (250 µM) or in the presence of GUDCA (50 µM) during 24 and 72h. As 
observed in Fig. IV.8, treatment with GUDCA alone caused no changes in cell 
viability at both time points, as it was expected. Also anticipated was the significant 
decrease induced by TMZ, a little more pronounced when time of incubation 
changed from 24 (19%, p<0.01) to 72 h (31%, p<0.01). A parallel study 
accomplished with the U-118 MG grade III human glioma cell line obtained a 
reduction of 43% in the cell proliferation at 72 h and with 250 µM TMZ (Carmo et al., 
2011). However, and this is relevant, the incubation of TMZ in the presence of 
GUDCA largely enhanced the effect of TMZ alone, further reducing the cell in 31% at 
24 h and in 17% at 72h (p<0.05). 
 
Fig. IV.8. Cell viability of GL261 cells in the absence (control) or in the presence of temozolomide 
(TMZ), glycoursodeoxycholic acid (GUDCA), and TMZ+GUDCA. Glioma cells were treated with 250 
μM TMZ or 50 μM GUDCA alone or in combination during 24 h and 72 h. To assess cellular viability and 
functionality, we used the MTS reduction assay. Data are expressed as percentage ± SEM of the value 
obtained for the control at each incubation period. **p<0.01, *p<0.05 vs. control; #p<0.05 vs. TMZ.  
 
The chemoresistance of GL261 after 72 h of TMZ treatment with more than 60% 
cells alive, may result from the subpopulation of cells that are known to be 
responsible for propagation of glioblastoma growth after chemotherapy (Chen et al., 
2012). Increased sensitization by combined therapy as here observed with GUDCA 
was already indicated for other compounds, such as a blocker of base excision repair 
(Montaldi and Sakamoto-Hojo, 2012), inhibitors of histone deacetylases (Ryu et al., 
2012), antiangiogenic (Den et al., 2012), autophagic (Lin et al., 2012) and non-
apoptotic inducers (Overmeyer et al., 2011), inhibitors of Mrp1 activity (Peignan et 
al., 2011), among many other proposals. We may then assume that dual (or even 
triple) targeting directed delivery systems are promising strategies against glioma. 
Given the beneficial effects evidenced by the combined treatment TMZ+GUDCA, 
we thought to next assess the effect of these treatments on the cell cycle and to 
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determine whether the reduced cell viability was related to an increase in apoptosis. 
The cell cycle analysis was performed by flow cytometry and in this technique the 
cells to be analyzed must be very well dissociated, avoiding the formation of cell 
aggregates. However, our cells formed these cellular bulks very easily, hindering the 
readings and leading to the absence of results, which happened very frequently, 
particularly concerning the untreated (control) cells. Therefore, in the absence of 
some control values, it was very difficult to ascertain the role of TMZ in the cell cycle 
of GL261 cells, which was never described. However, this effect was already studied 
by other and it was described that different cell lines possess distinct TMZ effects on 
cell cycle (Zhang et al., 2010), depending on their resistance this drug. In fact, while 
Hirose et al indicated that TMZ led to cell cycle arrest in G2, whit an accumulation of 
cells at this phase, Carmo et al reported that TMZ did not induced cell cycle arrest 
nor in G1 or G2 (Carmo et al., 2011). 
Due to the above described method limitations, and in the absence of trusting 
control values, we decide to present our results in a way that we can ascertain about 
the cell cycle effect of TMZ+GUDCA co-incubation (Table IV.1.). As in cell viability, 
the more significant results were obtained at the 72h incubation period. At this 
timepoint, we have observed that TMZ plus GUDCA has induced cell cycle arrest at 
the G2 phase, since there is an accumulation of cells at this check point (2.7-fold 
increase vs. TMZ alone, p<0.01). Consequently, the number of cells at the S phase 
have further decreased has compared to TMZ (0.6-fold, p<0.05). Interestingly, similar 
results were obtained by Yuan et al, that found that the combination of resveratrol 
and TMZ significantly resulted in G2/M cell cycle arrest in a model of GBM (Yuan et 
al., 2012). Since GUDCA is also an antioxidant molecule, we may speculate that it 
may share some of the already mechanisms by which resveratrol increase TMZ 
efficacy. 
Nonetheless, cell cycle of GL261 cells after treatments with either GUDCA or 
TMZ alone or TMZ in the presence of GUDCA were characterized by a low apoptotic 
fraction (data not shown), which prove that the reduction of cell viability is not related 
with apoptosis. Due to the described limitations of the used cell cycle analysis 
method, further assays should be performed using other procedures to analyse the 
cell cycle, such as the expression of some cell cycle related proteins. 
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Table IV.1. Cell cycle analysis of GL261 cells incubated in the presence of temozolomide 
(TMZ), glycoursodeoxycholic acid (GUDCA) and TMZ+GUDCA, during 24 and 72.  
Incubation conditions 
 
Cell cycle phase 
(fold change from TMZ) 
 
 
G0/G1 S G2/M 
24h 
 
 
 
72h 
TMZ 
GUDCA 
TMZ+GUDCA 
 
TMZ 
GUDCA 
TMZ+GUDCA 
1.00±0.37 
0.97±0.02 
0.79±0.01 
 
1.00±0.18 
1.46±0.10 
1.03±0.08 
1.00±0.01 
   0.89±0.01** 
  0.98±0.001 
 
1.00±0.13 
 0.74±0.05* 
 0.63±0.07* 
1.00±0.01 
   0.61±0.05** 
1.09±0.02 
 
1.00±0.49 
0.66±0.15 
 2.66±0.44* 
 
Glioma cells were treated with TMZ (250 μM) alone or in the presence of GUDCA (50 μM) during 24 
and 72 h. Results are expressed as mean fold change from TMZ±SD).  **p<0.01 and *p<0.05 vs. TMZ. 
  
Overall, we can postulate that GUDCA can be useful as an adjuvant molecule for 
TMZ, particularly when used in therapeutic schemes with longer administration 
periods. 
 
3.3. Effect of TMZ, MK-571 and TMZ+MK571 on glioma cells viability and cell 
cycle 
Mrp1 transporters have been associated to drug efflux and resistance to 
chemotherapy in high-grade gliomas, showing an average expression of 51.3% in 
glioma specimens. Moreover, as no changes were detected between primary or 
recurrent gliomas, it is suggest that chemoresistance is mostly intrinsic (Calatozzolo 
et al., 2005), therefore, strategies to decrease the expression of the MRP gene have 
been enlightened (Matsumoto et al., 2004). In line with this, the inhibitor 
indomethacin has shown to significantly increase the cytotoxic effect of etoposide, 
and even more that of vincristine (Benyahia et al., 2004). MK-571 is a specific Mrp1 
inhibitor, which may improve TMZ treatment, as it did for vincristine and etoposide 
(Peignan et al., 2011). However, these authors did not observe a beneficial effect by 
the combination of MK571 and TMZ when working with T98G and G44 GBM cell 
lines and suggest that TMZ may not be a substrate for Mrp1. However they only 
used TMZ at 100 µM and MK-571 (20 µM) for 24 h. As we showed in Fig. IV.7, this 
concentration of TMZ only slightly decreased the cell viability of our GL261 cell line. 
Therefore, we decided to test the combined effects of TMZ+MK-571 in our model. 
GL261 cells were treated (or untreated) with 250 µM TMZ alone or TMZ in the 
presence of MK-571 (25 µM) during 24 and 72 h, as pre-established. Once again, 
like GUDCA, MK-571 appears to be innocuous for the cells  (Fig. IV.9), but caused a 
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significant reduction in cell viability when associated to TMZ. Thus, the effect caused 
by TMZ treatment in the inhibition of MTS reduction by GL261 cells, already 
previously noticed, was here potentiated in a dose- and time-dependent manner in 
the presence of MK-571 at 24 h (~8% more vs. TMZ alone, p<0.05) increasing at 72h 
(~14% more, vs. TMZ alone, p<0.05).  
 
Fig. IV.9 Cell viability of GL261 cells in the absence (control) or in the presence of temozolomide 
(TMZ), Mrp1 inhibitor (MK-571) and TMZ+MK-571. Glioma cells were treated with 250 μM TMZ or 25 
μM MK-571 alone, or in combination during 24 and 72 h. To assess cellular viability and functionality, 
we used the MTS reduction assay. Data are expressed as percentage ± SEM of the value obtained for 
the control at each incubation period. . **p<0.015 and *p<0.05 vs. control; 
#
p<0.05 vs. TMZ alone.  
  
Once more, after cell viability assay, we have studied the effect of MK-571 and 
TMZ co-incubation in the cell cycle, using the same approach used for GUDCA 
studies, regarding the presentation of the results (Table IV.2). Similarly to GUDCA, 
higher and more significant variations were obtained at the 72h incubation period. 
We have observed that TMZ and GUDCA co-incubation provoked cell cycle arrest at 
the G2/M phase, which is observed by the accumulation of cells (2.8-fold increase 
vs. TMZ alone, p<0.01). Consequently, the number of cells at the S phase have 
further decreased has compared to TMZ (0.6-fold, p<0.01). Once more, this additive 
effect of MK-571 is not related with an increase in apoptotic cells (data not shown). 
Overall, these results suggest that inhibition of Mrp1 transporter may enhance 
TMZ therapy, its efficacy, particularly when used in therapeutic schemes with longer 
administration periods, as postulated for GUDCA. 
Gliomas comprise of significant cell heterogeneity that contains a number of 
cancer stem-like cells that may contribute to the resistance to treatment. These cells 
are phenotypically similar to the normal stem cells of the corresponding tissue of 
origin, but they exhibit dysfunctional patterns of self-renewal and differentiation (Jin 
et al., 2010) and have more growing ability during chemotherapy than that of 
glioblastoma cells. 
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Table IV.2. Cell cycle analysis of GL261 cells incubated in the presence of temozolomide (TMZ), 
MK-571 and TMZ+GUDCA, during 24 and 72.  
 
Incubation conditions 
 
Cell cycle phase 
(fold change from TMZ) 
 
 
G0/G1 S G2/M 
24h 
 
 
 
72h 
TMZ 
MK-571 
TMZ+MK-571 
 
TMZ 
MK-571 
TMZ+MK-571 
 
1.00±0.37 
0.97±0.02 
0.75±0.02 
 
1.00±0.18 
  1.60±0.07** 
1.04±0.09 
1.00±0.01 
   0.85±0.02** 
 1.00±0.09 
 
1.00±0.13 
   0.63±0.03** 
   0.62±0.11** 
1.00±0.01 
   0.79±0.01** 
1.14±0.24 
 
1.00±0.49 
0.70±0.27 
 2.81±0.36** 
 
Glioma cells were treated with TMZ (250 μM) alone or in the presence of MK-571 (25 μM) during 24 and 
72 h. Results are expressed asmean fold change from TMZ±SD). **p<0.01 and *p<0.05 vs. TMZ. 
  
As it was already demonstrated that these glioblastoma stem-like cells have a 
higher Mrp1 expression than Mrp1 (Jin et al., 2010), we can speculate that the 
inhibition of this ABC transporter may be an important tool to decrease this 
chemoresistance phenomenon, which will open important avenues regarding glioma 
therapy. 
However, it should be interesting to further investigate the role of Mrp1 in the 
GL261 cell line. This way, further assays should include the study of the Mrp1 activity 
in glioma cells and the respective effect of TMZ and TMZ plus MK-571, to ascertain 
about the level of Mrp1 inhibition activity achieved by MK-571. Further studies on 
Mrp1 modulation can also include Mrp1 silencing in glioma cells. 
 
4. Effect of GUDCA and MK-571 in tumor cell migration  
Briefly, the results obtained in the previous assays showed that either GUDCA or 
the Mrp1 inhibitor, MK-571, in addition to TMZ, enhanced the efficacy of TMZ 
treatment alone. Taking this in account, we considered that it would be important to 
elucidate which mechanism is underlying the potentiation of TMZ therapy by these 
compounds. For that, we proceed to analyze the expression of CXCR4, known to 
promote motility and proliferation of glioma cells (Carmo et al., 2010), in an attempt 
to clarify if it modulates  cell migration. For this, GL261 cells with 3, 5 or 7 DIV were 
treated with either GUDCA or MK-571, during 24 and 72 h, using the same 
concentrations of previous assays (Fig. IV.10).  
 
 
Chapter IV – Results and discussion 
 58 
0
1
2
3
4
C GU Mk 25
C
X
C
R
4
 e
x
p
re
ss
io
n
 
 (
fo
ld
 c
h
a
n
g
e
 f
ro
m
 c
o
n
tr
o
l)
 24h 72h
CXCR4 
β-actin 
47 kDa 
 
42 kDa 
    C       GUDCA   MK-571 
CXCR4 
β-actin 
47 kDa 
 
42 kDa 
24 h 
 
72 h 
    C       GUDCA   MK-571 
C              GUDCA     MK-571 
GL261 3DIV 
0
1
2
3
4
C GU Mk 25
C
X
C
R
4
 e
x
p
re
ss
io
n
  
(f
o
ld
 c
h
a
n
g
e
 f
ro
m
 c
o
n
tr
o
l)
 
CXCR4 
β-actin 
47 kDa 
 
42 kDa 
    C       GUDCA   MK-571 
CXCR4 
β-actin 
47 kDa 
 
42 kDa 
    C       GUDCA   MK-571 
24 h 
 
72 h 
C              GUDCA     MK-571 
GL261 5DIV 
0
1
2
3
4
C GU Mk 25
C
X
C
R
4
 e
x
p
re
ss
io
n
 
(f
o
ld
 c
h
a
n
g
e
 f
ro
m
 c
o
n
tr
o
l)
 
CXCR4 
β-actin 
47 kDa 
 
42 kDa 
    C       GUDCA   MK-571 
CXCR4 
β-actin 
47 kDa 
 
42 kDa 
    C       GUDCA   MK-571 
24 h 
 
72 h 
C              GUDCA     MK-571 
GL261 7DIV 
A) 
 
 
 
 
 
 
 
 
 
B)  
 
 
 
 
 
 
 
 
 
 
 
C)  
 
 
 
 
 
 
 
 
 
 
Fig. IV.10. CXCR4 expression in glioma cells at 3, 5 and 7 days in vitro in the absence 
(control) or in the presence of either glycoursodeoxycholic acid (GUDCA) ot the Mrp1 inhibitor 
MK-571. Glioma cells were not-treated or treated with 50 μM GUDCA or 25 μM MK-571 during 24 and 
72 h. Total cell lysates were analyzed by Western blotting with an antibody specific for CXCR4. Results 
of analysis of 3, 5 and 7 DIV (A, B and C, respectively) are shown by representative results from one 
experiment.and graph bars representing the intensity of the bands quantified by scanning densitometry, 
standardized with respect to β-actin protein and expressed as mean ± SEM fold change from respective 
control (accepted as 1). 
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We have observed that CXCR4 was constitutively expressed in GL261 cells, as 
demonstrated in other cell glioma lines (Carmo et al., 2010). Both compounds, 
GUDCA and MK-571 seem to induce the expression of CXCR4, mainly after 72 h 
incubation. While GUDCA evidence a preferential induction on glioma cells at 3 DIV, 
decreasing thereafter (from 2.1-fold to 0.8-fold vs. control), MK-571 suggests more 
efficacy on GL261 at 7 DIV. Although only two experiments were performed, both 
GUDCA and MK-571 revealed to have no effect if used for 24 h, but indeed induced 
(despite not significantly) an increase in the expression of CXCR4. Therefore, none 
of the compounds tested showed to be CXCR4 antagonists, what is usually looked 
for glioma therapy (Terasaki et al., 2011; Fareh et al., 2012; Yu et al., 2012). 
However, due to other beneficial effects, they can be given for periods that do not 
surpass the 24 h. Anyway, since only 2 assays were performed we still should 
confirm the results acquired and determine whether the chemokine to this receptor, 
the CXCL12 (also stroma-derived factor 1. SDF-1) is actually released. This feature 
is relevant once it was demonstrated an alternative receptor, the CXCR7 with a 10 
times higher affinity for SDF-1 (Balabanian et al., 2005) and also controls cell 
proliferation and migration (Odemis et al., 2012).  
Moreover, there are studies showing that CXCL12 alone cannot induce glioma 
formation, and that CXCR4 inhibition does not attenuate gliomagenesis in a mouse 
model of Neurofibromatosis-1 (NF1)-associated optic pathway glioma (OPG) (Sun et 
al., 2010). Re-evaluation of the roles of GUDCA and MK-571 on CXCR7 and CXCR4 
will be then important as targets to be modulated by therapy to glioma. Additionally it 
will be interesting to evaluate the effects of both compounds on MMPs activity once 
we saw that they were increasingly expressed at 3 DIV by GL261 cells (Fig. IV.2) 
and its action is mediated through the SDF-1/CXCR4 axis (Bhoopathi et al., 2011). 
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The study of tumorigenesis and the evaluation of new therapies for glioma 
require accurate brain tumor models. Cultures of malignant cells represent an 
excellent and permanent material for studying the biology of these tumors as, for 
example, specific antigens characterization, bioactive factors produced, 
determination of cellular proliferation, as well as heterogeneity of genotypic and 
phenotypic characteristics (Machado et al., 2005). Our GL261 glioma cell line 
characterization demonstrated that the cells express both undifferentiated (as 
Vimentin, Nestin, Sox2, as well βIII-Tubulin) and differentiated proteins (as GFAP, 
GLAST and MAP2), which levels change during the time in culture (Fig. V.1). This is 
in agreement with the cellular heterogeneity found in other glioma cell lines 
containing cells at different stages of differentiation (Shiras et al., 2003; Gangemi et 
al., 2009; Zhang et al., 2011) and to what was observed in human glioma (Bonavia et 
al., 2011). Therefore, this cell line has shown suitable characteristics for cellular and 
molecular studies, as well as for new trearment strategies for glioma, reason why it 
was used in the present study. 
In this study, we have evaluated the GL261 cells characteristics throughout time 
in culture, which is unusual to find in the literature, but it might be fundamental to 
better understand in which way cell markers and certain essential features progress 
along tumor cell differentiation. In fact, we hypothesize that a good cell 
characterization will allow the correlation of the grade of maturation of the cells with 
the grade of malignancy. This information will be very useful for a more directed 
therapeutic targeting, especially if we want to use a cell model that can mimic the 
stages with highest resistance.  
Regarding the evaluation of tumor-related factors either in glioma cells or in NS 
and respective differentiating astrocytes, though not as evident as it was expected, 
the results suggest that the initial stage, the proliferating NS, is the phenotype that 
presents more similarities with tumor cells concerning the majority of the evaluated 
tumor factors (Table.V.1). Thus, this may indicate that gliomagenesis could be 
related with malignant transformation of NSC, as suggested by many authors (Shiras 
et al., 2003; Gangemi et al., 2009), which is not surprising due to the similarities 
between both populations. However, based on some contradictory results along the 
maturation process of glioma cells, future research on this tumorigenic process is 
needed in order to confirm such hypothesis. Thus, our initial thoughts were to induce 
a glioma phenotype in both NSC and differentiating astrocytes to look which 
produced phenotype would be closer and acquire the same tumorigenic properties of 
glioma cells. This cell transformation could be performed by silencing both for the 
RNA of the lipid phosphatase PTEN and the tumor suppressor factor p53 by using 
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the respective siRNA, as it is described that this double inactivation cooperates to 
induce high-grade malignant gliomas (Zheng et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. V.1. Summary of GL261 cell line characterization. Schematic representation of the cellular 
markers expression along time in culture (3, 5 and 7 days in vitro – DIV). Throughout time, there was a 
variable expression of these markers. Sox2 and βIII-tubulin expression decreased from 3 to 7 DIV, while 
vimentin increased till 5 DIV and then remained constant. GFAP (glial fibrillary acidic protein) suffered a 
reduction from 5 to 7 DIV, while GLAST (glutamate aspartate transporter) and MAP2 (microtubule-
associated protein 2) revealed a peak expression level at 5 DIV. 
 
Treatment of glioma cells with TMZ in the presence of GUDCA or MK-571 greatly 
enhanced the effect of TMZ alone, causing a further loss of cell viability, specially at 
72 h. In addition, at the same conditions, it was observed an accumulation of cells at 
G2/M phase, corresponding to a cell cycle arrest at this checkpoint. Moreover, both 
co-incubation schemes showed low apoptotic levels, which indicates that the 
decrease of cell viability is not correlated with this type of cell death. Overall, our 
results suggest that GUDCA and MK-571 can act as adjuvants of TMZ therapy, 
particularly when used in therapeutic schemes with longer administration periods. 
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Intriguingly, either GUDCA or MK-571 seems to improve the migratory ability of 
GL261, by the induction of increase of CXCR4 levels, although with distinct patterns. 
 
Table. V.1. Characterization of common features between GL261 glioma cells and neurospheres 
induced to differentiate into astrocytes during 3 and 7 days in vitro. 
 
 
The expression of the tumor-related factors is represented from the lowest (+) to the highest expression 
(+++). The green, red and blue squares represent, for each evaluated factor, the phenotype more 
similar to neurospheres (NS) or to 3 and 7 DIV differentiating astrocytes. The analysis of tumor-related 
factors showed that during GL261 maturation, there is a decrease on the expression of the vascular 
endothelial growth factor (VEGF) as well as on the activity of the matrix metalloproteinases MMP-9 and 
MMP-2, which is associated with an increase on S100B release. Also, the Mrp1 presents a peak of 
expression at 5 DIV. Overall, but not as evident as we expected. NS is the phenotype that present the 
highest similarities with GL261 cells. LC3, light chain 3, LC3II/LC3I ratio; Mrp1, multidrug resistance-
associated protein 1; MMPs, matrix metalloproteinases; VEGF, vascular endothelial growth factor.  
 
Due to these contradictory findings, the therapeutic potential of GUDCA and 
Mrp1 modulation should be further investigated by using in vivo studies. Thus, in a 
near future we propose to use these molecules in association with TMZ in an in vivo 
model of glioma, where tumors will be generated by intracerebral implantation of the 
GL261 glioma cells in rats (Doblas et al., 2010). We anticipate that these therapeutic 
schemes will inhibit tumor cell growth and prevent vascular alterations in early stages 
of glioma progression. 
Interestingly, the factors with highest impact face to non-glioma cells were 
S100B, VEGF and Mrp1, in agreement with their fundamental role in glioma 
development. Taking this in account, these factors may be potential therapeutic 
targets and, subsequently, it would be interesting to further evaluate the synergistic 
effect of TMZ and GUDCA or MK-571 on these tumor related features. 
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The overall goal is to translate these results into the clinical practice, which will 
reduce the resistance to the commonly used chemotherapeutic drugs, increasing the 
survival of brain tumor patients. 
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